N-ACETYLGLUCOSAMINYLTRANSFERASE V CODING SEQUENCES

Abstract: The present invention provides a substantially purified UDP-N-acetylglucosamine: alpha -6-D-mannoside beta -1,6-N-acetylglucosaminyltransferase (GlcNAc T-V; EC 2.4.1.155) and antibodies which specifically bind GlcNAc T-V. The present invention also provides polynucleotide sequences and oligonucleotide probes capable of specifically hybridizing to nucleic acid sequences which encode GlcNAc T-V, and cDNA and genomic clones encoding GlcNAc T-V, as well as nucleotide sequences encoding GlcNAc T-V, as specifically exemplified by a GlcNAc T-V coding sequence from rat.

Description: N-ACETYLGLUCOSAMINYLTRANSFERASE V CODING SEQUENCES Field of the Invention The field of this invention is the area of protein glycosylation, specifically the area of the particular enzyme, UDP N-acetylglucosaminyltransferase V, involved in the expression of the β(l,6) branch structure found in tri- and tetraantennary N-linked oligosaccharides. The field relates to purified active enzyme, the amino acid sequence of the rat enzyme protein, genes encoding active enzyme and cell lines genetically engineered to express a nucleotide sequence encoding active enzyme. Background of the Invention UDP-N-acetylglucosamine:α-6-D-mannoside β-1,6-N- acetylglucosaminyltransferase V (GlcNAc T-V; EC 2.4.1.155) is the Golgi enzyme responsible for the synthesis of the β(l,6) branch structure of tri- and tetraantennary N-linked oligosaccharides. For brevity, this enzyme is abbreviated GlcNAc T-V herein. GlcNAc T-V activity has been found in many mammalian tissues and cell types. Altered glycosylation of membrane glycoproteins and glycolipids is observed in mammalian cells transformed with diverse tumor viruses, carcinogens, or transfection with certain oncogenes. In some cases, there is a quantitative increase in a particular substituent, e.g. , sialylation. In other instances, there is the reappearance of an oligosaccharide structure in the tumor which is normally only found in fetal tissue; for instance, certain Lewis histo-blood group antigens have been detected in adenocarcinomas. Qualitative differences in oligosaccharides may also be observed in certain transformed cells. BHK fibroblasts transformed with polyoma virus or with Rous sarcoma virus display more highly branched complex N-linked oligosaccharides than do the corresponding normal cells. The expression of the β-1,6 branch structure (-[GlcNAc-β(l,6)Man-α(l,6)Man]-) found in tri- and tetraantennary N-linked oligosaccharides is increased in the transformed cells. This has been correlated with a 2 to 3-fold increase in the specific activity of GlcNAc T-V. Transformation of murine cells with polyoma viruses, adenovirus, tumorigenic DNA and either the ras or the fps/fes oncogenes also resulted in increased GlcNAc T-V activity. By contrast, several other glycosyl transferases involved in N- linked glycosylation are unchanged in the transformed cells. The mechanism for the increased specific activity of GlcNAc T- V in transformed cells is not known. The increase in the β(l,6) branching of the cell surface- bound oligosaccharides has been associated, at least in some cases, with capacity for metastasis. Increased levels of β- 1,6 branching over the level in normal tissue has been observed for some human breast tumor tissues. The purification of the rat kidney GlcNAc T-V has been published (Shoreibah et al. (1992) J. Biol. Chem. 267:2920- 2927). Summary of the Invention An object of this invention is the N- acetylglucosaminyltransferase V enzyme and DNA sequences encoding a protein having this enzymatic activity. Substantially pure and/or recombinantly-produced GlcNAc T-V will be useful in in vitro, and recombinant host cells expressing a GlcNAc T-V coding sequence will be useful for in vivo glycosylation reactions. Provided herein are genomic and cDNA sequences encoding glcNAc T-V, amino acid sequences of GlcNAc T-V enzymes, and recombinant host cells genetically engineered to express a sequence encoding an active GlcNAc T-V enzyme. Also provided by this invention are polyclonal and monoclonal antibodies specific for rat kidney GlcNAc T-V. These antibodies will also bind to and be useful for detection and isolation of GlcNAc T-V from other mammalian sources. It is understood that the molecular weight, kinetic parameters and primary amino acid sequence of GlcNAc T-V from a source other than rat kidney may vary from those characteristics disclosed herein for the rat kidney enzyme. Another object of this invention is GlcNAc T-V produced by recombinant DNA technology in prokaryotic or eukaryotic host cells. Disclosed herein this invention is the complete amino acid sequence for GlcNAc T-V from rat and a complete nucleotide sequence encoding GlcNAc T-V from rat. Exemplary methods of producing recombinant active GlcNAc T-V by recombinant DNA technology are disclosed herein. The exemplified amino acid sequence and the nucleotide sequence encoding GlcNAc T-V, and subsequences within, as understood in the art, will be useful for isolating GlcNAc T-V coding sequences from a wide range of species and for producing useful quantities of GlcNAc T-V by recombinant DNA technology. Further objects of this invention are cDNA clones encoding GlcNAc T-V and genomic clones encoding GlcNAc T-V. Antibodies raised against rat kidney GlcNAc T-V or to conjugated peptides derived therefrom, for example, from analysis of the amino acid sequence of GlcNAc T-V disclosed herein, using art known methods for analysis and conjugation, can be used to detect expression of GlcNAc T-V from sources other than rat kidney by virtue of cross-reactivity with those other GlcNAc T-V enzymes; alternatively, these antibodies can be used to screen cDNA expression libraries. Similarly, the degenerate oligonucleotide probes and/or the coding sequence and/or the amplimer sequences of the present invention can be used to screen genomic or cDNA libraries constructed using nucleic acids from mammalian sources other than rat kidney, or these can be used to prepare primers to amplify sequences encoding GlcNAc T-V from mRNA populations prepared from rat kidney or from other mammalian sources. The cDNA and/or genomic sequences encoding GlcNAc T-V will be useful in directing the recombinant expression of GlcNAc T-V. Further objects of this invention are nucleotide sequences encoding rat GlcNAc T-V, and nucleotide sequences encoding GlcNAc T-V from other vertebrate, preferably mammalian, sources, including cDNA and genomic sequences. The nucleotide sequence encoding rat GlcNac T-V is provided herein as SEQ ID NO:15, from an ATG translation start codon beginning at nucleotide 299 through a translation stop codon ending at nucleotide 2521. The skilled artisan recognizes that there will be more than one nucleotide sequence capable of encoding the same amino acid sequence due to the degeneracy of the genetic code. These sequences, and sequence variants thereof which encode functionally equivalent GlcNAc T-V, can be used to express GlcNAc T-V in a desired recombinant host cell. The GlcNAc T-V coding sequences from other vertebrate species, preferably from mammals, will be highly homologous at the nucleotide sequence level to the exemplified rat GlcNAc T-V coding sequence disclosed herein. Functionally equivalent GlcNAc T-V coding sequences with at least 70%, preferably at least 80%, more preferably at least 90%, nucleotide sequence homology to the exemplified rat GlcNAc T-V coding sequence can be identified and isolated from cDNA libraries prepared from MRNA sources other than rat cells, using well-known DNA-DNA hybridization technology and the exemplified rat GlcNAc T-V coding sequence provided herein. Also contemplated are genomic clones encoding GlcNAc T-V, which clones comprise the natural regulatory sequences. It is understood that any intron sequences in genomic clones encoding GlcNAc T-V are not to be included in sequence comparisons to the exemplified full-length rat coding sequence. Additional objects of this invention are DNA molecules containing a first nucleotide sequence encoding an enzymatically active GlcNAc T-V and a second nucleotide sequence not found associated with the GlcNAc T-V coding sequence in nature, termed an exogenous nucleotide sequence herein. Preferably the first nucleotide sequence encodes a polypeptide sequence with GlcNAc T-V activity, said polypeptide having an amino acid sequence as given in SEQ ID NO:16. Still further objects of the invention are cells genetically engineered to contain a DNA molecule containing a first nucleotide sequence encoding an enzymatically active GlcNAc T-V and a second nucleotide sequence not found associated with the GlcNAc T-V coding sequence in nature. Mammalian cells are preferred for recombinant expression of GlcNAc T-V coding sequences. Particularly preferred are COS-7 cells and CHO (Chinese Hamster Ovary) cells. The exemplified rat GlcNAc T-V amino acid sequence is particularly preferred, preferably encoded by the exemplified nucleotide coding sequence as in SEQ ID NO:15 from nucleotide 299 through nucleotide 2521. Brief Description of the Drawings Figure 1 is a reproduction of an ethidiu bromide-stained agarose gel, showing the reaction products of the results of PCR amplification of GlcNAc T-V coding sequences. Lane 1 contains molecular weight standards (123 ladder) ; Lanes 2 and 7 were the results of reactions containing mouse lymphoma cell line BW5147 CDNA from total RNA as a template; Lanes 3 and 8 were the results of reactions containing mouse lymphoma cell line BW5147 cDNA from poly(A)+ RNA as template; Lanes 4 and 9 were the results of reactions containing rat mammary tumor cell line MAT Cl cDNA from total RNA as template; Lanes 5 and 10 were the results of reactions containing rat mammary tumor cell line MAT Cl cDNA from poly(A)+ RNA as template; and Lanes 6 and 11 were the results for reactions without added template. The reactions run in Lanes 2-6 were carried out with Primer 1 (SEQ ID NO:5) and Antiprimer 2 (SEQ ID NO:8) as the primers for PCR. In the reactions run in Lanes 7-11 were carried out with Primer 2 (SEQ ID NO:7) and Antiprimer 1 (SEQ ID NO:6) . Figure 2 illustrates autoradiograms resulting from Southern hybridizations using radiolabeled 200 amplimer (PCR product) prepared using rat mammary tumor cell line MAT Cl cDNA from poly(A)+ RNA as template and Primer 1 (SEQ ID NO:5) and Antiprimer 2 (SEQ ID NO:8) as primers. Figure 5A shows the results for Bglll-digestion. Fig. 5B the results for Ncol/Xhal digestion, Fig. 5C for Ncol digestion and Fig. 5D for BamHI/Bglll digestion. In each panel, lane 1 contains digested MAT Cl genomic DNA and lane 2 contains digested rat liver genomic DNA. Figure 3 is a reproduction of an ethidium bromide-stained agarose gel, showing the products obtained after PCR amplification of Rat 1-EJ library cDNA sequences. Lane 1 contains molecular weight standards (Molecular Weight Marker II, Boehringer Mannheim, Indianapolis, IN) ; Lane 2 contains molecular weight standards (Molecular Weight Marker VII, Boehringer Mannheim) ; Lane 3 contains an aliquot of PCR reaction products resulting from amplification of Rat 1-EJ cDNA using primer T7:476-30 (SEQ ID NO: 11) and primer B:474- 16 (SEQ ID NO: 10) . Figure 4 is a reproduction of an autoradiogram resulting from the Southern hybridization of the DNA transferred from the gel illustrated in Figure 3 in reverse orientation after it was probed with primer A:474-14 (SEQ ID NO: 9). Figure 5 is a reproduction of an ethidium bromide-stained agarose gel, showing the products obtained after PCR amplification of an approximately 2.1 kb PCR product that was visualized in the autoradiogram in Figure 4. Lane 1 contains molecular weight standards (Molecular Weight Marker VII, Boehringer Mannheim) ; Lane 2 contains the PCR products obtained after amplification of the approximately 2.1 kb PCR fragment with primer T7:476-30 (SEQ ID NO: 11) and primer 485- 26: (SEQ ID NO: 12); Lane 3 contains molecular weight standards (Molecular Weight Marker II, Boehringer Mannheim) . Figure 6 presents the sequences of partial GlcNAc T-V coding sequences, termed amplimer sequences herein, from mouse (SEQ ID NO:17), rat (SEQ ID NO:18), and human (SEQ ID NO:19). Colons (:) indicate identical bases. There appear to be 13 differences between mouse and rat and two differences between mouse and human, as determined from comparison of the available sequences. Detailed Description of the Invention In general, the terminology used herein is standard, as understood by those of ordinary skill in the fields of molecular biology, biochemistry, protein chemistry, and cell biology. For added clarity, certain terms are defined herein. Standard abbreviations are. used; these abbreviations are consistent with those used and approved by scientific journals in the field (e.g.. Journal of Biological Chemistry, Science, Nature, etc.) . Methods used herein are either specifically referenced or are sufficiently well known as to be available in at least one of several readily accessible published collections of methodologies (See, e.g., Sambrook et al. (1989) Molecular Cloning. A Laboratory Manual (2nd ed.). Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, Innis et al. (1990) PCR Protocols: A Guide to Methods and Applications. Academic Press, New York, New York, and references cited therein, all incorporated herein by reference) . Complementary DNA (cDNA) synthesis involves the .in vitro synthesis of a double stranded DNA sequence by enzymatic reverse transcription of mRNA isolated from donor cells. In the present invention, polyadenylated RNA is prepared from rat 1-EJ cultured cells (described in Peles et al. (1992) Cell .69:205-216). Rat 1-EJ cells are Rat 1 fibroblasts which have been transfected with the human EJ gene, an activated Harvey ras gene, which is believed to elevated expression levels for GlcNAc T-V. cDNA molecules and/or libraries can be used for isolating a DNA sequence encoding a selected protein when the entire amino acid sequence of that protein is not known. Isolating a gene from a cDNA library is made much easier when at least a partial amino acid sequence is known, and is further facilitated when a complete coding sequence from at least one species is known. Procedures for the preparation of cDNA sequences in plasmid libraries derived from the reverse transcription of mRNA are well-known to the art. The polymerase chain reaction (PCR) provides a powerful alternative to cDNA cloning for the amplification of sequences encoding a selected protein when at least a partial sequence of the selected protein is known. A degenerate oligonucleotide sequence is prepared according to the complement of the sequence encoding the partial amino acid sequence, and this degenerate oligonucleotide (i.e., a family of sequences) is used to prime PCR synthesis using cDNA derived from polyadenylated RNA as template. Further oligonucleotides for priming PCR are derived from unique (i.e., known) nucleotide sequences. Expression refers to the transcription and translation of a structural gene (coding sequence) so that a protein having the biological activity of GlcNAc T-V is synthesized. The term expression control sequence refers to a DNA sequence that controls and regulates the transcription and translation of another DNA sequence (i.e., a coding sequence). A coding sequence is operatively linked to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that coding sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene. As used herein, an exogenous nucleotide sequence is one which is not in nature covalently linked to a particular nucleotide sequence, e.g., a GlcNAc T-V coding sequence. Examples of exogenous nucleotide sequences include, but are not limited to, plasmid vector sequences, expression control sequences not naturally associated with particular GlcNAc T-V coding sequences, and viral vector sequences. Similarly, as used herein an exogenous gene is one which does not naturally occur in a particular recombinant host cell but has been introduced in using genetic engineering techniques well known in the art. An exogenous gene as used herein can comprise a GlcNAc T-V coding sequence expressed under the control of an expression control sequence not associated in nature with said coding sequence. Another feature of this invention is the expression of the sequences encoding GlcNAc T-V. As is well-known in the art, DNA sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate host cell. A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, nonchro osomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., Escherichia coli plasmids ColEl, pCRl, pBR322, pMB9 and their derivatives, plasmids such as RP4; phage DNAs, e.g., M13 derivatives, the numerous derivatives of phage λ, e.g., λgtll, and other phage DNA; yeast plasmids derived from the 2μ circle; vectors useful in eukaryotic cells, such as insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; baculovirus derivatives; and the like. For mammalian cells there are a number of well-known expression vectors available to the art. Any of a wide variety of expression control sequences may be used in these vectors to express the DNA sequences of this invention. Such useful expression control sequences include, for example, the early and late promotes of SV40 or adenovirus for expression in mammalian cells, the lac system, the trp system, the TAC or TRC system, the major operator and promoter regions of phage λ, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase of phosphatase (e.g., pho5) . the promoters of the yeast α-mating factors, and other sequences know to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. The skilled artisan understands which expression control sequences are appropriate to particular vectors and host cells. A wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well-known eukaryotic and prokaryotic hosts, such as strains of E. coli. Pseudomonas. Bacillus. Streptomyces. fungi such as yeasts, and animal cells, such as CHO, Rl.l, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS-7, BSC1, BSC40, and BMT10) , insect cells (e.g., Sf9) , and human cells and plant cells in culture. It is understood that not all combinations of vector, expression control sequence and host cell will function equally well to express the DNA sequences of this invention. However, one skilled in the art will be able to select the proper vector, expression control sequence, and host cell combination without undue experimentation to accomplish the desired expression without departing from the scope of this invention. In selecting a suitable expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the promoter, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, e.g. , with regard to potential secondary structure. Suitable unicellular hosts will be selected by consideration of factors including compatibility with the chosen vector, secretion characteristics, ability to fold proteins correctly, and fermentation requirements, as well as any toxicity to the host of the product encoded by the DNA sequences to be expressed. and the ease of purification of the expression products. The practitioner will be able to select the appropriate host cells and expression mechanisms for a particular purpose. N-acetylglucosaminyltransferase V (GlcNAc T-V) denotes the enzyme UDP-N-acetylglucosamine:α-6-D-mannoside β(l,6)-N- acetylglucosaminyltransferase (EC 2.4.1.155). This enzyme is responsible for the synthesis of β-1,6 branch structure (- [GlcNAc-β-(l,6)Man-α(l,6)Man]-) found in both tri-and tetra¬ antennary N-linked oligosaccharides. Several strategies are available for the isolation and purification of recombinant GlcNAc T-V after expression in a recombinant host system. One method involves expressing the proteins in bacterial cells, lysing the cells, and purifying the protein by conventional means. Alternatively, one can engineer the DNA sequences for secretion from cells. See Example 11 and/or Colley et al. (1989) J. Biol. Chem. 264:17619-17622. which reference describes purifying a sialyltransferase by engineering the cleavable signal peptide of human gamma-interferon onto the DNA sequence for the transferase. Larsen et al. (1990) Proc. Natl. Acad. Sci. USA 87 . :6674-6678, fused the DNA sequence for protein A to the amino-terminal end of a fucosyl transferase gene and expressed it as an excreted fusion protein. In such a construction, one can optionally remove the transmembrane region from near the 3' end of the coding sequence. After secretion the proteins are purified from the medium. Similar strategies are available for bacterial expression systems. It is understood by those skilled in the art that the exemplified rat GlcNAc T-V coding sequence, provided herein in SEQ ID NO:15 from nucleotide 299 through nucleotide 2521, is representative of GlcNAc T-V from other vertebrate sources, especially of other mammalian sources, including humans. The coding sequence for rat GlcNAc T-V provided herein is suitable for use in preparing or deriving PCR primers for identifying and/or amplifying sequences encoding human or other animal GlcNAc T-V, and/or for use as hybridization probes to identify clones encoding human or rat, other mammalian or other vertebrate GlcNAc T-V in appropriate genomic or cDNA libraries. The techniques for the purification of the rat kidney GlcNAc T-V disclosed herein will be understood to be applicable to the purification of human or other GlcNAc T-V to a level comparable to that of rat kidney GlcNAc T-V. The skilled artisan recognizes that routine modifications of the procedures disclosed herein may provide improved results in isolating nonexemplified GlcNAc T-V enzymes. Species other than rat, including mouse and human, contain genes encoding proteins which catalyze the same enzymatic reaction as rat GlcNAc T-V, which genes have significant nucleic acid sequence homology to the rat sequence encoding GlcNAc T-V. One can isolate these homologous genes using the DNA sequences of this invention as probes or primers under standard hybridization conditions. This invention specifically contemplates and encompasses such sequences. A comparison of limited nucleotide sequence data (about 160-180 bases of "amplimer" sequence) from within the coding sequences of rat (SEQ ID NO:17), mouse (SEQ ID NO:18), and human (SEQ ID NO:19), obtained by PCR amplification of mRNA using primers disclosed herein, revealed significant sequence conservation; at least about 90% nucleotide sequence homology was observed in rat-mouse and rat-human comparisons (See Fig. 6) . Thus, GlcNAc T-V coding sequences from vertebrate sources will have significant sequence homology to the exemplified rat GlcNAc T-V coding sequence provided herein. The ordinary skilled artisan can utilize the exemplified sequence or portions thereof preferably at least 25-30 bases in length, in hybridization probes to identify cDNA (or genomic) clones encoding GlcNAc T-V, where there is at least 70% sequence homology to the probe sequence using appropriate art-known hybridization techniques. The skilled artisan understands that the capacity of a cloned cDNA to encode functional GlcNAc T-V enzyme can be readily tested as taught herein (See Example 11) . Hybridization conditions appropriate for detecting various extents of nucleotide sequence homology between probe and target sequences and theoretical and practical consideration are given, for example in B.D. Hames and S.J. Higgins (1985) Nucleic Acid Hybridization. IRL Press, Oxford, and in Sambrook et al. (1989) supra. Under particular hybridization conditions the DNA sequences of this invention will hybridize to other DNA sequences having sufficient homology, including homologous sequences from different species. It is understood in the art that the stringency of hybridization conditions is a factor in the degree of homology required for hybridization. The skilled artisan knows how to manipulate the hybridization conditions so that the stringency of hybridization is at the desired level (high, medium, low) . If attempts to identify and isolate the GlcNAc T-V gene from another mammalian source fail using high stringency conditions, the skilled artisan will understand how to decrease the stringency of the hybridization conditions so that a sequence with a lower degree of sequence homology will hybridize to the sequence used as a probe. The choice of the length and sequence of the probe is readily understood by the skilled artisan. When a cDNA library is used as a source of GlcNAc T-V coding sequences, the skilled artisan will take steps to insure that the library is of high quality, i.e., that rare mRNAs will be represented and that large mRNAs (larger than about 3 kb) will be present as full length cDNA clones. If the artisan uses one of the commercially available or otherwise accessible cDNA libraries, he will choose one that meets the criteria taught herein. Providing for rare and/or large message representation is within the skill of the art. The DNA sequences of this invention refer to DNA sequences prepared or isolated using recombinant DNA techniques. These include cDNA sequences, sequences isolated using PCR, DNA sequences isolated from their native genome, and synthetic DNA sequences. As used herein, this term is not intended to encompass naturally-occurring chromosomes or genomes. Sequences derived from the GlcNAc T-V gene can be used in studying the regulation of GlcNAc T-V expression in normal cells, in transformed cells and in metastatic tumor cells, and can be used in designing mechanisms, e.g., via antisense RNA or DNA, for inhibiting metastasis of tumor cells. These sequences can also be used to direct recombinant synthesis of GlcNAc T-V. Expression of recombinant DNA molecules according to this invention may involve post-translational modification of a resultant polypeptide by the host cell. For example, in mammalian cells expression might include, among other things, glycosylation, lipidation or phosphorylation of a polypeptide, or proteolytic cleavage of a signal sequence to produce a "mature" protein. Accordingly, as used herein, the term "GlcNAc T-V" encompasses full-length polypeptides and modifications or derivatives thereof, such as glycosylated versions of such polypeptides, mature proteins, polypeptides retaining a signal peptide, truncated polypeptides having comparable biological activity, and the like. Expression of GlcNAc T-V in eukaryotic cell lines expressing biologically active glycoproteins will allow efficient branch structure initiation directed by GlcNAc T-V, where desired. Rat kidney is useful as a source of GlcNAc T-V for purification because of the commercial availability of relatively large quantities of the tissue. The purification and relevant techniques of rat kidney GlcNAc T-V is described in Shoreibah et al. (1992) supra and in Examples 1-5. The data are summarized in Table 1. A survey of mouse, hamster and rat tissues had revealed that kidney was one of the most abundant sources of the enzyme in these rodents. The substantially pure GlcNAc T-V from rat kidney migrates predominantly as a doublet of 69 and 75 kDa on 10% SDS- polyacrylamide gels. This enzyme preparation is stable in the presence of 20% glycerol for several months when stored at 4°C. TABLE 1 PURIFICATION OF RAT KIDNEY N-ACETYLGLUCOSAMINYLTRANSFERASE V Results described below are based on a preparation of the enzyme from 300 g of frozen rat kidneys Total Specific Step Volume Protein Activity Activity Yield Purificatio ml mg nmol/h nmol/(mg-h) -fold Rat kidney acetone powder 3,300 13,900 2,221 0.16 100 Triton X-100 extract UDP-hexanola ine-Sepharose Inhibitor-BSA-Sepharose To confirm that the two major SDS-PAGE protein bands (69 and 75 kDa) resulting from the two column purification scheme comprised GlcNAc T-V, an aliquot of the purified enzyme preparation was re-chromatographed on a 1 ml UDP-hexanolamine- agarose column. The bound material was eluted using several stepwise elutions of the ligand UDP, instead of the single concentration of NaCl, as used in the first chromatographic step. Almost no activity was detected in either the fractions eluted using a UDP concentration of 10 or 20 mM. Fifty mM UDP displaced the majority of the GlcNAc T-V activity from the column. A small peak was eluted using 50 mM UDP plus 150 mM NaCl. As judged by the silver staining pattern, rechromatography did not result in further increases in purity of the GlcNAc T-V. Similar results were obtained when a sample material resulting from the two column purification scheme were re-chromatographed on the inhibitor-BSA affinity column. Once the GlcNAc T-V was substantially purified, the assay conditions were optimized. Enzymatic activity was stabilized and enhanced by the inclusion of 20% glycerol and 0.5 mg/ml IgG. The optimal pH range for the substantially pure GlcNAc T-V was 6.5 to 7.0; optimal Triton X-100 concentration was in the range of about 1.0 to about 1.5%. Enzyme activity was maximal at about 0.2 M NaCl, and was inhibited at higher salt concentrations. Divalent cations had a minimal effect on apparent enzyme activity when added as MnCl 2 , CaCl 2 or MgCl 2 , and the addition of 20 mM EDTA did not appear to be inhibitory. Using the optimized assay conditions, kinetic parameters were determined for the substantially pure GlcNAc T-V enzyme. The apparent K___ for the oligosaccharide acceptor (βGlcNAc(l,2)αMan(l,6)βMan-0-(CH 2 ) 8 COOCH 3 ) was 87 μM, and the apparent K m for UDP-GlcNAc was 11.0 mM. The apparent V maχ for the sugar nucleotide was 18.8 μmol/ ( g-min) . For amino acid sequence analysis, the enzyme was further purified by preparative SDS-PAGE using an Applied Biosystems High Performance Electrophoresis Apparatus (Applied Biosystems, Foster City, California) . The fractions containing enzyme were pooled and concentrated. The enzyme protein was then precipitated by ethanol addition and lowering the temperature to (-20°C) . The precipitate was collected by centrifugation, washed and dried. NH 2 -terminal amino acid sequencing was attempted, but the results indicated that the N-terminus of the protein was blocked. A sample of the substantially purified rat kidney GlcNAc T-V was digested using immobilized trypsin, separated from the immobilized trypsin and the peptides within the digest were then separated by reverse phase HPLC using a 2.1 x 150 mm VYDAC C18 column, eluted with a gradient of acetonitrile. Four peptide peaks were chosen for gas phase sequencing. The results were as follows: Peak #34 AsnThrAspPhePhelleGlyLysProThrLeuArg (SEQ ID NO:l) Peak #49 AlalleLeuAsnGlnLysIleGluProTyrMetProTyrGluPheThr (SEQ ID NO:2) Peak #28 ValLeuAspSerPheGlyThrGluProGluPheAsn (SEQ ID NO:3) Peak #61 SerAspPro[Cys]TyrAla[Asp]Tyr[Glu]Val (SEQ ID NO:4) Bracketed amino acid residues were assigned with some uncertainty. The amino acid sequences obtained from the four peaks were searched within the Swiss Protein Data Bank and deduced degenerate coding sequences were searched in the Genbank database. No significantly homologous sequences were found. The determination of a partial amino acid sequence for GlcNAc T-V allows the production of sets of degenerate oligonucleotide probes or primers, thus, enabling the cloning of the corresponding cDNA and genomic clones. Those oligonucleotides can also be used to study the transcriptional and/or translational mechanisms which control the level of expression of the gene encoding GlcNAc T-V. From the amino acid sequences for the internal peptides corresponding to peaks 34 and 49, corresponding degenerate oligonucleotides were designed for use as primers for PCR amplification of cDNA sequences encoding GlcNAc T-V. Abbreviations for nucleotides used herein are in accordance with IUPAC practice: A is adenosine; C is cytosine; G is guanosine; T is thymidine; I is inosine; R is A or G; Y is C or T; H is A or C or T; D is G or A or T; and N is A or C or G or T. The degenerate 29 base oligonucleotide designed from the sequence of first ten amino acids of the Peak 34 peptide is presented as Primer 1 (SEQ ID NO:5). The antisense counterpart (SEQ ID NO:6) of Primer 1, termed AntiPrimer 1 herein, will be useful as a primer in the PCR amplification of sequences encoding GlcNAc T-V present within polyadenylated mRNA populations, prepared from cells including, but not limited to, rat kidney, mouse lymphoma BW5147 cells and ascites-grown rat mammary gland tumor MAT Cl cells. Primer 1: AAYACIGAYTTYTTYATHGGIAARCCNAC (SEQ ID NO:5) AntiPrimer 1: GTIGGYTTICCDATRAARAARTCIGTRTT (SEQ ID NO:6) (antisense) A second degenerate 29 base oligonucleotide was designed using the sequence of the last ten amino acids of the peptide corresponding to Peak 49: Primer 2: ATHGARCCITAYATGCCITAYGARTTYAC (SEQ ID NO:7) AntiPrimer 2: TCRTAIGGCATRTAIGGYTCDATYTTYTG (SEQ ID NO:8) (antisense) The antisense primers given above can also be used to amplify mRNA encoding GlcNAc T-V in polymerase chain reactions. Other oligonucleotide primers and "antiprimers" may be designed using the peptide sequences and/or GlcNAc T-V sequences disclosed herein by one of ordinary skill in the art for use in priming PCR synthesis of GlcNAc T-V coding sequences. The sequences of the antisense primers (AntiPrimers 1 and 2; SEQ ID NO:6 and SEQ ID NO:8) are complementary to those of the corresponding Primers 1 and 2, respectively (SEQ ID NO:5 and SEQ ID NO:7). Either the sense or the antisense primers, or preferably the PCR amplification product of Primer 1 and AntiPrimer 2, can be used as hybridization probes or as PCR primers for screening a rat kidney cDNA library, a rat genomic library or mouse libraries for clones encoding GlcNAc T-V. The primers and antisense primers in appropriate combination can be used to prime PCR reactions using cDNA prepared, for example, from rat kidney cell poly(A)+ RNA. Sequences amplifiable with these primers and antisense primers in PCR reactions will be those encoding portions of GlcNAc T-V. For PCR amplification of sequences encoding GlcNAc T-V, Primer 1 and AntiPrimer 2 cDNA were used to prime PCR-directed DNA synthesis. The combination of Primer 2 (SEQ ID NO:7) and AntiPrimer 1 (SEQ ID NO:6) did not yield an amplification product from either cell line. Using cDNA prepared from poly(A)+ RNA from either the rat mammary tumor line MAT Cl or from the mouse lymphoma cell line BW5147 with Primer 1 and AntiPrimer 2, an amplification product of about 200 bp was obtained, as shown in Fig. 1. The rat amplimer DNA sequence is given in Fig. 6 and SEQ ID NO:18. Background signal was reduced substantially by using 55°C rather than 50°C as the annealing temperature in the PCR reactions. The results also indicate a high degree of homology between the GlcNAc T-V coding sequences in mouse and rat. Thus, the primer/antiprimer sequences disclosed herein will be useful in identifying GlcNAc T-V genes and coding sequences of sources other than rat. The amplimer made by PCR with cDNA from MAT Cl poly(A)+ RNA as template and Primer 1 (SEQ ID NO:5) and AntiPrimer 2 (SEQ ID NO:8) was 32 P-labeled for use as a hybridization probe. Rat MAT Cl genomic DNA and rat liver genomic DNA were digested in separate restriction endonuclease reactions, the fragments were separated in parallel using agarose gel electrophoresis, blotted to support and DNA-DNA hybridization was carried out under standard hybridization conditions of low stringency. Hybridization patterns were consistent with a single genetic locus encoding GlcNAc T-V in each. Figure 2 illustrates the autoradiogram obtained for Southern hybridization with rat mammary tumor cell line MAT Cl and for rat liver genomic DNA. With Bglll, BamHI/Bglll and Ncol digestion, the size of the unique hybridizing genomic band is between 2 and 10 kbp. With Ncol/Xhal digestion, the size of the hybridizing band is between roughly 6 and 9 kb. Routine experimentation will allow size estimation with more precision. The roughly 180 bp amplimer used in this experiment can be used to screen cDNA or genomic libraries to identify GlcNAc T-V sequences. Standard "walking" experiments can be performed to obtain the sequences which flank the hybridizing fragment(s) after cloning of that fragment so that the entire gene can be isolated. Labeled oligonucleotides having sequences of Primers 1 and 2 (SEQ ID NO: 5 and 7) or AntiPrimers 1 and 2 (SEQ ID NO:6 and SEQ ID NO:8), or preferably the PCR amplification product (amplimer) made using Primer l and AntiPrimer 2 as primers, can be successfully used as hybridization probes for screening cDNA libraries prepared from sources including mouse lymphoma BW5147 cells, mouse 3T3 cells and ascites-grown rat mammary gland MAT-C1 cells for sequences encoding GlcNAc T-V. When a Hindlll/Bglll restriction fragment from within the coding region of a partial mouse cDNA clone was used as a hybridization probe in a Northern blot of rat kidney mRNA size separated by agarose gel electrophoresis, a band of about 7 5 kb, along with apparent degradation products, was displayed. * ' Thus, the size of the GlcNAc T-V MRNA is large, and care must be taken in preparing (or in choosing) a cDNA library from which to isolate a full length GlcNAc T-V coding sequence. Examples 7-10 describe the steps in the successful 10 identification and cloning of the rat GlcNAc T-V coding sequence using a PCR-cDNA strategy. In other experiments, an amplimer of about 170-200 bases was prepared by PCR. This amplimer was used to screen a mouse cDNA library, and a partial clone of about 1.7 kb was isolated. Sequence analysis 15 revealed that the long open reading frame did not contain a start codon, and about 300 amino acids were determined by the open reading frame. A series of PCR amplification and screening steps were carried out using plasmid DNA prepared from pools of cDNA clones from subsets of a cDNA library 20 prepared from Rat 1-EJ cell mRNA (See Examples 7-8) . A rat cDNA clone of about 4.8 kb, carrying the full length GlcNAc T-V coding sequence was isolated. A portion of the cDNA was sequenced; the resulting DNA sequence is presented in SEQ ID NO:15. The coding sequence extends from 25 an ATG start codon beginning at nucleotide 299 through a stop codon ending at nucleotide 2521. Six potential N- glycosylation sites occur at asparagine residues at amino acid numbers 109, 114, 117, 333, 430, and 446. A putative transmembrane domain encompasses amino acids 14-30. 30 Approximately 300 bp of 5' untranslated sequence is presented, followed by 2220 bp of coding sequence and about 100 bp of the 3' untranslated region. The deduced amino acid sequence is given in SEQ ID NO:16. The predicted molecular weight (84,561) of the encoded GlcNAc T-V is larger than the protein bands observed in SDS-PAGE gels. When GlcNAc T-V is purified from rat kidney by in the presence of a cocktail of protease inhibitors in vast excess, a band of about 95 kDa, in addition to the 69 and 75 kDa bands, is observed. When a radioactive photoaffinity active site label was used to tag active enzyme, all three bands were labeled. These observations suggest that the 75 and 69 kDa bands represent proteolytic fragments of the larger protein. The 95 kDa band is likely to represent a glycosylated form of the polypeptide encoded in SEQ ID NO:15. Six potential sites for N-linked glycosylation were identified: Asn residues at amino acid positions 109, 114, 117, 333, 432, and 446 in SEQ ID NO:16. A putative transmembrane domain, extending from amino acids 14-30, was identified by hydrophobicity analysis using Kyte and Doolittle methodology. This proposed transmembrane domain is characteristic of type II membrane proteins, and is similar to other enzymes of the lumen of the Golgi apparatus. Within the deduced amino acid sequence of rat GlcNAc T-V (SEQ ID NO:16), the sequences corresponding to the Peak #s 34, 49 and 28 peptide sequences (SEQ ID NOS:1-3) were located at amino acids 546-557, 592-607, and 375-386, respectively. The amino acid sequence of Peak #61 (SEQ ID NO:4) occurs at amino acids 168-177 in SEQ ID NO:16. The identities of the cysteine and aspartate residues are confirmed, and the amino acid at the ninth position in SEQ ID NO:4 was deduced to be glycine rather than glutamate, based on SEQ ID NO:15. It is well-known in the biological arts that certain amino acid substitutions can be made within a protein without affecting the functioning of that protein. Preferably such substitutions are of amino acids similar in size and/or charge properties. For example, Dayhoff et al. (1978) in Atlas of Protein Seguence and Structure. Volume 5, Supplement 3, Chapter 22, pages 345-352, which is incorporated by reference herein, provides frequency tables for amino acid substitutions which can be employed as a measure of amino acid similarity. Dayhoff et al.'s frequency tables are based on comparisons of amino acid sequences for proteins having the same function from a variety of evolutionarily different sources. ' 5 Two mouse GlcNAc T-V partial clones have been sequenced. The deduced partial mouse sequence was compared to corresponding rat GlcNAc T-V amino acids 387-740 as in SEQ ID NOS:15-16. From the preliminary sequences, the only deduced amino acid difference in the available mouse sequence was at 10 the position corresponding to amino acid 679 of rat. The rat deduced amino acid is isoleucine whereas the mouse amino acid is threonine. A comparison of the available nucleotide sequences over the coding region revealed that there was about 96% sequence homology; a comparison of 103 available bases of 15 rat sequence with mouse sequence in the 3 ' noncoding region revealed about 88% sequence homology. Thus, the coding and the noncoding sequences (at the 3' end) are highly conserved between mouse and rat, especially within the coding region, where nucleotide differences are in all but one case silent. 20 The 4.8 kb cDNA insert determined by partial DNA sequence analysis to contain an apparently full length GlcNAc T-V coding sequence was subcloned into the pJT-2 expression vector and electroporated into COS-7 cells (See Example 11) . After 3 or 4 days incubation after the electroporation, the 25 transfected cells were harvested, frozen and subsequently assayed for GlcNAc T-V activity. Parallel preparations of cells transfected with pJT-2 without insert DNA served as controls. It was estimated that about 3% of the cells were effectively electroporated. The data in Table 2 indicate that ' 30 the cloned rat cDNA fragment encodes a functional GlcNAc T-V enzyme. Table 2. GlcNAc T-V Activity in the Transient Expression Assay Sample COS-7 (pJT-2) COS-7 (pJT-2- It will be a matter of routine experimentation for the ordinary skilled artisan to use the DNA sequence information presented herein to optimize GlcNAc T-V expression in a particular expression vector and cell line for a desired purpose. A cell line genetically engineered to contain and stably express a GlcNAc T-V coding sequence will be useful for the recombinant expression of protein products with the characteristic glycosylation dependent on GlcNAc T-V modification of glycoproteins. Any means known to the art can be used to introduce an expressible GlcNAc T-V coding sequence into a cell to produce a recombinant host cell, i.e., to genetically engineer such a recombinant host cell. Recombinant host cell lines which express high levels of GlcNAc T-V will be useful as sources for the purification of GlcNAc T-V, e.g., for studies of inhibitors of GlcNAc T-V activity for preventing or slowing metastasis of tumors. The coding sequence of GlcNAc T-V will be useful in preparing an antisense construct specific for GlcNAc T-V for inhibiting GlcNAc T-V expression where that is desired, for example, in metastasizing tumor cells. The following examples are provided for illustrative purposes as well as for enablement. These examples are not intended to limit the scope of the invention. The examples use many techniques well known and accessible to those skilled in the arts of molecular biology and biochemistry. It will be readily apparent to the skilled artisan that modifications of the methods disclosed herein may be made, and that there will be DNA sequence modifications which can be made with the maintenance of the desired result. It will be readily apparent to one of ordinary skill in the art that the nucleotide sequences and amino acid sequences disclosed herein make it unnecessary to repeat many of the examples to practice the invention. All references cited in this application are expressly incorporated by reference herein. EXAMPLES Example l. Preparation of UDP-Hexanolamine-Agarose UDP-hexanolamine was prepared and linked to CNBr- activated SEPHAROSE 4B according to the procedure in Barker et al. (1972) J. Biol. Chem. 247:7135-7147. The substitution of the SEPHAROSE (Pharmacia, Piscataway, N.J.; agarose) at a level of 14 μmoles of UDP-hexanolamine per ml of settled gel is critical; substitution levels of 6 and 9 μmoles per ml gave significantly lower activity yields. Exam le 2. Purification of GlcNAc T-V from Rat Kidney Frozen rat kidneys were purchased from Pel-Freez Biological, Inc. (Rogers, Arkansas) . Three hundred g of frozen rat kidneys were homogenized in 3 liters of cold acetone in a Waring blender at 4°C. All subsequent steps were also performed at 4°C unless otherwise noted. The acetone-insoluble material was collected on Whatman filter paper no. 4. The acetone insoluble material was re-homogenized in acetone and refiltered. The resulting powder was stirred in 1.8 liters Buffer A (0.1 M sodium acetate (pH 6.0), 0.2 M NaCl, 0.01 M EDTA) for 30 min. The residue was collected by centrifugation for 15 min at 7100 x g. The pellet was again extracted with Buffer A and centrifuged again. The resulting pellet was then stirred in 2 liters water and collected by centrifugation. To the washed residue was then added the following protease inhibitors: 0.1 mM PMSF, 0.05 mg/ml aprotonin, 0.5 mg/ml soybean trypsin inhibitor, 0.5 μg/ml leupeptin, and 1 μg/ml pepstatin. This mixture was then homogenized in 1 liter Buffer B (0.01 M Tris-HCl (pH 7.8), 0.4 M KC1. The resulting homogenate was brought to 1% Triton X-100 (w/v) and stirred 30 min. The suspension was centrifuged for 20 min at 7100 x g to give the first extract (the supernatant) . The pellet was twice again homogenized, solubilized with Triton X-100, and clarified by centrifugation to yield the second and third extracts. The three extracts were pooled and dialyzed against 20 liters Buffer C (50 mM MES pH 6.5, 0.2% (w/v) Triton X-100, 5 mM EDTA, 0.05% sodium azide over a 72 hr period with a single change of dialysis buffer. The resulting dialysate was clarified by centrifugation and then assayed for protein concentration and enzymatic activity. In the first affinity chromatography step, 3 1 of acetone powder Triton extract was applied to a 1.2 x 7 cm column of UDP-hexanolamine Sepharose pre-equilibrated with Buffer C. The column was then washed with about 400 ml Buffer C. The column was then eluted with Buffer C plus 0.5 M NaCl. Fractions were collected and assayed for GlcNAc T-V activity. Pooled fractions (about 100 ml) eluted from the UDP- hexanolamine SEPHAROSE column were dialyzed against Buffer C. The dialyzate was brought to 1 mM UDP-GlcNAc and 20% glycerol and was loaded on a 1.2 x 3 cm column of inhibitor-BSA- Sepharose pre-equilibrated with Buffer D (50 mM MES pH 6.5, 0.1% Triton X-100, 20% glycerol, 0.05% sodium azide. The column was then washed with 20 ml Buffer D without UDP-GlcNAc. Finally the column was stopped, brought to room temperature, and then eluted with the inclusion of 500 mM NaCl in Buffer D in which the pH had been adjusted to 8.0. Fractions were collected and assayed for GlcNAc T-V activity. An aliquot (0.1 ml) of the pooled active fractions from the inhibitor-BSA affinity column was then dialyzed against Buffer C and applied to a 0.4 x 8 cm column of UDP- hexanolamine Sepharose pre-equilibrated with Buffer D. The column was then eluted with buffers comprising increasing amounts of UDP in Buffer D: 10 mM UDP, 20 mM UDP, 50 mM UDP, 50 mM UDP with 120 mM NaCl and finally 100 mM UDP with 150 mM NaCl. Fractions were collected and assayed for GlcNAc T-V activity. (For this purification step either Buffer D can be used or 50 mM sodium cacodylate pH 6.5, 0.1% Triton X-100, 20% glycerol, 0.05% sodium azide can be used, with incremental increases in NaCl concentration for elution as described for Buffer D.) Equal volumes from each set of fractions were concentrated under reduced pressure and elevated temperature with a Speed Vac. SDS-polyacrylamide gel electrophoresis of various fractions was carried out on 10% SDS-polyacrylamide gels after the concentrated samples were boiled in 1 X gel sample buffer to reduce and denature the proteins (Laemmli (1970) Nature 227:680-685) . The gels were silver-stained as described in Morrisey (1981) Anal. Biochem. 117:307-310 in order to visualize the material. Example 3. Assay of GlcNAc T-V Activity A typical radiochemical assay for determining activity during purification contained the following reagents which were dried in vacuo in a 1.5 ml conical centrifuge tube: 2 mM ADP (pyrophosphatase inhibitor, 2.5 mM βmethylGlcNAc (β- hexosaminidase inhibitor), 10 6 cpm UDP-[6- 3 H]-GlcNAc (10 cpm/pmol) and 1 mM of the synthetic acceptor (β-D-GlcNAc)- (l,2)-α-D-Man-(l,6)-β-D-Man-0-(CH 2 )gC0 2 Me in a total volume of 10 microliters. To initiate the reaction, 0.01 ml of sample, in a buffer containing 50 mM MES pH 6.0, 0.1% Surfact-Amps (Triton) X-100 (Pierce, Rockford, Illinois) , was added to the dried reagents and incubated at 37°C for several hrs. To terminate the assay, 0.5 ml water was added to each tube, vortexed thoroughly, and the contents of the tubes were centrifuged. The supernatant was then loaded onto a pellicular C18 Sep-Pak column (Millipore, Bedford, Massachusetts) activated with methanol and pre-equilibrated with water. The columns were washed with 200 ml water to remove water-soluble radioactivity resulting from unreacted substrate and degradation products. The radiolabeled product of the GlcNAc T-V reaction was then eluted with a 0-100% step gradient of methanol, and radioactivity was quantitated by liquid scintillation counting. All assays were conducted in duplicate, and the results were averaged. In tabulating the results for Table I, assays were done in at least two separate experiments and averaged. The variation between the values derived from duplicates or from separate experiments did not exceed ±10% and typically were less than ±2% of the averaged values. Radiolabeled product was then separated from the unreacted acceptor and radiolabeled UDP-GlcNAc by virtue of the hydrophobic moiety using C-18 chromatography. Once the GlcNAc T-V protein was purified, the parameters in the assay were optimized: 20% glycerol, near physiological levels of NaCl (about 200 mM) , 0.5 mg/ml IgG, pH about 6.5 - 7.0, and Triton X-100 concentration about 1.0-1.5%. GlcNAc T-V protein was measured using the enzyme-linked immunosorbent assay described in Crawely et al. (1990) Analytical Biochem 185:112-117. The ELISA uses unlabeled UDP- GlcNAc and a trisaccharide acceptor (β-D-GlcNAc)-(l,2)-α-D- Man-(l,6)-β-0-Man-D-(CH 2 ) 8 C0 2 Me coupled to BSA. This assay relied on the use of a polyclonal antibody specific for the tetrasaccharide-BSA product of the GlcNAc T-V reaction. Due to the extreme sensitivity of the ELISA, column fractions column fractions containing an inhibitory amount of NaCl, for example, could be assay without prior dialysis by simply diluting the samples. Standard calibration curves were generated in each assay and absorbance (or relative activity) was correlated to a specific activity by comparison to values obtained for a sample of known GlcNAc activity, as measured in the radiochemical assay. Example 4. Measurement of Small Amounts of Protein The BCA protein assay (Pierce, Rockford, Illinois) was adapted for use in a microtiter plate format using standard polystyrene 96 well plates (Pierce, Rockford, Illinois) to assay column fractions for protein content during purifications. BSA served as the standard protein. Example 5. Preparation of Inhibitors. Acceptors. Substrates and Affinity Adsorbents UDP hexanolamine was synthesized and linked to CNBr- activated agarose support (SEPHAROSE 4B) as described in Barker et al. (1972) J. Biol. Chem. 242:7135-7147. The concentration of the ligand relative to the support was 14 μmoles per ml of settled gel. The deoxy oligosaccharide inhibitor of GlcNAc T-V activity (n-octyl 6-0-[2-0-(2-acetamido-2-deoxy-β-D- glucopyranosyl)-6-deoxy-α-D-mannopyranosyl]-β-D- glucopyranoside) was synthesized as described in Palcic et al. (1990) J. Biol. Chem. 265:6759-6769. and used in assays. A similar GlcNAc T-V oligosaccharide inhibitor (βGlcNAc(l,2) 6-deoxy-α-Man(l,6) βMan-0-(CH 2 ) 8 COOCH 3 was coupled to BSA according to the method of Pinto et al. (1983) Carbohydr. Res. 124:313-318 for use as an affinity chromatography ligand. The ligand in the column is an active site inhibitor which mimics the natural oligosaccharide acceptor of GlcNAc T-V, but contains a hydrogen in place of the reactive 6'-hydroxyl. The inhibitor oligosaccharide (4.1 mg) was converted to the acyl azide as a 25 mM solution in DMF (dimethyl formamide) at -15°C and then 222.2 mg BSA (Sigma Chemical Co., St. Louis, Missouri) was added in 2 ml of 0.35 M KHC0 3 and 0.07 M Na 2 B 4 0 7 (pH 9.0). The resulting solution was held at 4 C for 24 h, and then extensively dialyzed against distilled water on a Amicon PM-10 ultrafiltration membrane (Amicon, Inc., Division of WR Grace, Danvers, Massachusetts). The dialysate was then lyophilized, and redissolved. Protein content was measured using the Bradford assay (Bradford (1976) Analyt. Biochem. 21:248-254) with BSA as a standard. Carbohydrate content was measured using the phenol-sulfuric acid method (Dubois et al. (1956) Analyt. Chem. 28:350-356) . The results indicated that 13 oligosaccharide molecules were incorporated per molecule of BSA (67% coupling) . The coupling of 3.6 mg of the inhibitor-protein complex to 3 ml of periodate-oxidized agarose (SEPHADEX CL-6B, Pharmacia, Piscataway, New Jersey) was carried out as described in Stults et al. (1989) Analyt. Biochem. 180:114-119 with NH 2 (CH) 2 OH-HCl as the final blocking reagent. A coupling of 34% of the oligosaccharide-BSA complex to the agarose gave a final incorporation of 0.07 μmol of ligand oligosaccharide per ml of settled gel as estimated by the Bradford protein assay. Trisaccharide oligosaccharide acceptors and their syntheses are described in Palcic et al. (1990) supra; Pierce et al. (1987) Biochem. Biophys. Res. Commun. 146:679-684: Arango et al. (1988) J. Cell. Biochem. 37:225-231; and Srivastava et al. (1988) Carbohydr. Res. 179:137-161. Example 6. Production of Antibodies specific for GlcNAc T-V GlcNAc T-V is precipitated from storage buffer by adding 3 volumes of absolute ethanol and left to stand for 30 min at 4°C. The precipitated protein is collected by centrifugation (10,000 x G for 10 min), resuspended in 0.3 ml of Buffer D, and mixed with 1.0 ml of Freund's complete adjuvant. The resulting emulsion is administered to two rabbits by injecting intradermally in the back with 50-75 μl/site or about 75 μg protein per site. Each rabbit receives booster injections of 150 μg per dose, prepared in the same way, 14 days after the initial dose, and each rabbit receives 75 μg at 21, 34, 57 and 64 days after the initial injection. 10-20 ml of blood is collected from an ear vein of each rabbit at weekly intervals, and serum is prepared and stored at -20°C. Relative levels of antibody specific for GlcNAc T-V are estimated by determining the amount of serum required to inhibit 50% of the activity in the assay using the artificial substrate as acceptor. Serum samples with the highest activity are pooled. Monoclonal antibodies specific for rat kidney GlcNAc T-V are prepared according to standard procedures (e.g., Campbell (1984) Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology (Burdon and van Knippenberg, eds.) Vol. 13, Elsevier, Amsterdam; Harlow and Lane (1988) Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) after immunization of mice with purified rat kidney GlcNAc T-V. Example 7. Isolation of PCR Fragment Containing Rat GlcNAc T-V Sequences A. Rat 1-EJ cDNA Library Construction The Rat 1-EJ cDNA library had been previously constructed. Messenger RNA was isolated by standard procedures (Maniatis et al., 1982) from Rat 1 cells which had been transfected with the human EJ gene, an activated Harvey ras gene (Peles et al. (1992) Cell 6.9:205-216). Poly (A) 4" mRNA was selected using an mRNA separator kit (Clontech Lab, Inc. , Palo Alto, CA) and cDNA was synthesized with the Superscript kit (BRL Life Technologies, Inc., Bethesda, MD) . Column-fractionated double-stranded cDNA was ligated into Sail and Notl-digested pSPORT-1 plasmid vector (BRL Life Technologies, Inc., Bethesda, MD) and transformed into Escherichia coli DH10B cells by electroporation (Dower et al. (1988) Nucl. Acids Res. 16.:6127-6145) The Sail site is on the 5' side and the Notl site is on the 3' side of the cDNA sequence of each clone. Transformed _______ coli DH10B cells were propagated as 43 individual pools and plasmid DNA was isolated from each pool. B. Design and Construction of Oligonucleotides The approximately 180 bp PCR amplimer sequences from mouse, rat, and human were analyzed, and specific oligonucleotides were designed covering areas where the mouse, rat and human sequences were identical. Primer A:474-14 GGGCCGATGAAGACTTCTGCG (SEQ ID NO: 9) (antisense) Primer B:474-16 GGGCTACTTCCTCTCGGTTATTGAG (SEQ ID NO: 10) (antisense) In addition, an oligonucleotide was designed using the T7 promoter sequence of the cloning vector pSPORT-1. Primer T7:476-30 GCTCTAATACGACTCACTATAGG (SEQ ID NO: 11) (sense) C. PCR Amplification of Rat 1-EJ cDNA Library Sequences An aliquot of plasmid DNA from each pool of the Rat 1-EJ cDNA library was combined to form a Rat 1-EJ cDNA library DNA mixture (Rat 1-EJ cDNA pool) . PCR was carried out on the Rat 1-EJ cDNA pool using primers T7:476-30 (SEQ ID NO: 11) and B:474-16 (SEQ ID NO: 10). The T7 sequence of pSPORT-1 lies upstream from the 5' Sail cloning site used in the cDNA synthesis. Therefore, PCR priming using the oligonucleotide T7:476-30 (SEQ ID NO: 11) synthesizes an amplimer covering the extreme 5' end of the cDNA and extending in the direction of the 3' end of the coding sequence. The PCR product extends into the coding sequence to the primer B:474-16 (SEQ ID NO: 10) which lies within the approximately 200 bp amplimer. PCR was carried out using a GeneAmp DNA Amplification Kit (Perkin Elmer Cetus, Norwalk, CT) according to the manufacturer's instructions. Briefly, a 100 μl reaction consisted of the following: 8 μl MgCl 2 25 mM 10 μl 10X PCR buffer 70.8 μl sterile H 2 0 2 μl dGTP 10 mM 2 μl dATP 10 mM 2 μl dTTP 10 mM 2 μl dCTP 10 mM 1 μl T7:476-30 primer 15 μM 1 μl B:474-16 primer 15 μM 500 ng Rat 1-EJ cDNA library pool DNA The reaction mix was overlayered with mineral oil (Sigma, St. Louis, MO) and placed in a DNA thermal cycler (Perkin Elmer Cetus). Taq polymerase (0.5 μl, 2.5 U) was added in a hot start procedure and the thermal cycler was programmed as follows: An aliquot of the reaction products was analyzed by agarose gel electrophoresis (0.8% agarose in Tris Borate EDTA buffer (TBE) containing ethidium bromide) and the gel was photographed (Figure 7) . One major band at approximately 1200 bp and several smaller minor species were visible on the ethidium bromide-stained gel. D. Southern Hybridization of PCR Products After PCR, products from Example 7, Part C, were separated by agarose gel electrophoresis and analyzed by a standard Southern blot procedure. Briefly, the gel was denatured by soaking in 1.5 M NaCl, 0.5 N NaOH for 30 min. The gel was then neutralized by soaking in 1.5 M NaCl, 0.5 M Tris-HCL (pH 7.5) for 30 minutes. The DNA in the gel was transferred to nitrocellulose by capillary action in 10X SSC overnight. After transfer, the nitrocellulose was rinsed in 6X SSC, air dried and crosslinked in a UV Stratalinker (Stratagene, La Jolla, CA) . The nitrocellulose was prehybridized, hybridized and probed using an Enhanced Chemiluminescence 3' Oligolabelling and Detection System kit (Amersham, Arlington Heights, IL) according to the manufacturer's instructions. Prehybridization was carried out at 50°C for 30 min. Hybridization was carried out for about one and a half hours at 50°C with approximately 8 ng/ml of oligonucleotide probe A: 474-14 (SEQ ID NO: 9) . After hybridization, the nitrocellulose was washed twice in 5X SSC, 0.1% SDS at room temperature for 5 min each time. Then the nitrocellulose was washed twice in IX SSC, 0.1% SDS at 50°C for 15 min each time. Horse Radish Peroxidase Antibody development and ECL detection were carried out according to kit instructions. The nitrocellulose was exposed to x-ray film at room temperature for 20 minutes. Autoradiography of the nitrocellulose revealed a single band of approximately 2.1 kb (Figure 8) . This specific, but rare, PCR product was not visible on the ethidium bromide-stained gel (Figure 2) . E. Amplification of Specific PCR Product Since the specific 2.1 kb PCR product described in Example 7, Part D was present in such minute quantities that it could only be detected by autoradiography, it was amplified by PCR. First, the 2.1 kb PCR product was isolated by cutting a region of an agarose gel in which the specific DNA was expected to have migrated. The DNA was eluted from the gel using an S&S Elu-Quik DNA Purification Kit (Schleicher & Schuell, Keene, NH) following the manufacturer's directions. A PCR reaction was carried out on an aliquot of the eluted DNA utilizing primer T7: 476-30 (SEQ ID NO: 11) at the 5' end. The 3' primer was as follows: 485-26 GGGTACGTGTGAATGATATCCAGGTAG (SEQ ID NO: 12) (antisense) This oligonucleotide sequence lies approximately 350 bp upstream from the 3' end of the 2.1 kb PCR fragment. This sequence was elucidated by sequencing a partial mouse cDNA which was isolated by screening a mouse lymphoma BW 5147 library with the approximately 200 bp PCR amplimer sequence. A 100 μl PCR reaction using the eluted 2.1 kb PCR fragment as template was prepared as follows: 8 μl MgCl 2 25 mM 10 μl 10X PCR buffer 61.5 μl sterile H 2 0 2 μl dGTP 10 mM 2 μl dATP 10 mM 2 μl dTTP 10 mM 2 μl dCTP 10 mM 1 μl T7: 476-30 primer 15 μM 1 μl 485-26 primer 15 μM 10 μl eluted 2.1 kb PCR fragment The reaction mix was treated as described in Example 7, Part C and the thermal cycler was programmed as follows: 40 cycles 72°C 10 min 4°C soak An aliquot of the reaction products was analyzed by agarose gel electrophoresis (0.8% agarose in TBE containing ethidium bromide) and the gel was photographed (Figure 4) . Analysis of the ethidium bromide-stained gel revealed a single DNA band of approximately 1.8 kb. F. DNA Sequence Analysis The approximately 1.8 kb PCR product described in Example 7, Part E was sequenced using Taq DyeDioxy Terminator cycle sequencing kits (Applied Biosystems, Inc., Foster City, CA) and an automated DNA sequencer (Applied Biosystems 373A) following the manufacturer's instructions. The PCR fragment was sequenced after it was passed over a Centricon-100 unit (Amicon, Beverly, MA) and washed with sterile water. In some instances, sequences were derived after the PCR fragment was subcloned into a pUC13 vector (Promega, Madison, WI) . Nucleotide sequencing was carried out using synthetic oligonucleotides as primers. Sequencing of approximately 1750 bp of the PCR fragment and analysis of all possible reading frames revealed overlap with the partial mouse BW 5147 cDNA sequence. The partial mouse cDNA contained 3' untranslated sequence as well as an open reading frame of approximately 885 bases which would code for approximately 295 amino acids, but no start codon. The sequencing of the PCR fragment extended the open reading frame coding region by an additional approximately 445 amino acid residues and located the methionine specifying ATG start codon. In addition, approximately 300 bp of 5' untranslated region was identified in the PCR fragment. Alternatively, cDNA clones encoding GlcNAc T-V can be isolated using the following strategy. Total RNA is prepared in parallel isolations from rat kidney tissue, according to standard procedures, and from mouse lymphoma BW5147 cells and from ascites-grown rat mammary gland MAT-C1 cells, as described in Sambrook et al. (eds.) (1989) SUPra. ATCC T1B47 is a clone (BW5147.3) of the BW5147 cell line adapted into culture (J. Natl. Cancer Inst. (1973). 5_1:883; J. Immunol. (1973) 110:1470) . MAT Cl cells are described in Carraway et al. (1976) J. Biol. Chem. 251:6173- 6178. The Poly(A)+ fraction of the total RNA is prepared by chromatography over Oligo(dT) cellulose chromatography as described in Sambrook et al. (eds.) (1989) supra. Polyadenylated mRNA encoding GlcNAc T-V is included within the Poly(A)+ RNA thus prepared. cDNA libraries are prepared using the poly(A)+ RNA prepared from rat kidney, mouse lymphoma BW5147 cells, and MAT-B1 cell total RNA according to the procedure of Sambrook et al. (eds.) (1989) supra. Cloning of the cDNA population into a suitable vector (such as λgtll) is done according to standard protocols. (See, e.g., Huynh et al. (1985) in DNA Cloning, a Practical Approach. Vol. 1 (Glover, D.M. , ed.), IRL Press, Washington, D.C., pp. 49-78). Commercially-available cDNA libraries (e.g., rat kidney cDNA library, Clontech Laboratories, Palo Alto, California) can also be screened for GlcNAc T-V clones. The cDNA libraries are screened for sequences encoding GlcNAc T-V by plaque hybridization under low stringency conditions using the approximately 200 bp amplimer radiolabeled by random hexamer labelling as described in Sambrook et al. (eds.) (1989) supra. Clones specifically hybridizing the amplimer sequence are selected for further analysis (restriction endonuclease digestion, nucleotide sequence determination) . Genomic clones encoding GlcNAc T-V can be identified from a rat (or mouse or other mammal) genomic library using Primer 1 (SEQ ID NO:5) or Primer 2 (SEQ ID N0:7) e.g., or Primers 1 and 2 in combination, or the amplimer where PCR synthesized as above was primed with Primer 1 (SEQ ID NO: 5) and AntiPrimer 2 (SEQ ID NO:8) to identify appropriate genomic sequences. From the clones analyzed it is possible to reconstruct the entire coding sequence of GlcNAc T-V. If a full-length coding sequence is not reconstructed, further primers can be designed using sequences near the ends of the sequenced region for use in the RACE procedure (Rapid Amplification of cDNA Ends) as described in Frohman et al. (1988) Proc. Natl. Acad. Sci. USA j35_:8998-9002. Where the entire gene is desired, genomic libraries can be screened, and "walking" procedures known in the art are used to extend in both directions. Example 8. Cloning of a Rat cDNA Sequence Encoding GlcNAc T-V A. Southern Hybridization of Rat 1-EJ Library Pools Nitrocellulose filters, containing Notl-linearized plasmid DNA from each of the individual 43 pools of the Rat 1- EJ cDNA library, were probed in order to identify which pool(s) contained a full-length GlcNAc T-V cDNA. A cDNA probe was derived from the partial mouse cDNA coding region and was obtained as a Hindlll/Pstl fragment starting approximately 855 bp down stream from the Rat 1-EJ PCR fragment ATG sequence and extending approximately 650 bp toward the 3' end of the sequence. The nitrocellulose filters were incubated with prehybridization solution at 42°C as described in Sambrook et al., (eds.) (1989) supra. Hybridization was then carried out in an overnight incubation using an approximately 650 bp mouse cDNA probe which was labeled with [α 32 P]-dCTP using a Multiprime DNA Labelling System kit (Amersham) . The nitrocellulose was then washed and the filters were exposed to X-ray film with an intensifying screen at -80°C overnight. Autoradiography of the filters revealed 4 positive pools among the 43 screened. B. PCR Analysis of Rat l-EJ Library Pools PCR was carried out using template DNA from each of the 4 positive Rat 1-EJ cDNA library pools identified in Example 8, Part A in order to determine which pool contained a full- length cDNA. The reactions were carried out as described in Example 7, Part C, except that the following primers were used: Primer 501-16 CCCGTCGACGAGAGCCAAGGGAATGGTAC (SEQ ID NO: 13) (sense) Primer 496-2 CCCAGCAGGTACAGAGATGTG (SEQ ID NO: 14) (antisense) Primer 501-16 (SEQ ID NO: 13) was determined by sequencing the Rat 1-EJ PCR fragment to hybridize in the 5' untranslated region approximately 15 to 35 bases upstream from the ATG start codon. Primer 496-2 (SEQ ID NO: 14) was determined by sequencing to hybridize within the coding region about 900 bases downstream from the ATG start coon. Therefore, PCR with these two primers gives a predicted product of about 900 bp in length covering the 5' end of the coding region. The thermal cycle was programmed as follows: 40 cycles 72°C 10 min 4°C soak An aliquot of the reaction mixture was separated by agarose gel electrophoresis as described in Example 7, Part C. Analysis of the ethidium bromide-stained gel indicated two of the four pools gave the correct size band (about 900 bp) . This information, together with the size of the bands obtained by Southern hybridization of the Rat 1-EJ cDNA library pools (Example 8, Part A) revealed that one pool could contain a full-length GlcNAc T-V cDNA. C. Colony Hybridization Procedures for Screening a Rat 1-EJ cDNA Library Pool Transformed ________ coli from the glycerol stock of the one pool of the Rat 1-EJ cDNA library identified in Example 8, Part B, above, were spread out at a density of approximately 4,500 colonies per 10 x 10 cm plate on nutrient plates containing 50 μg/ml Ampicillin. Nitrocellulose filters were used to lift the colonies off the plate. The filters (colony side up) were treated by serially placing them over a piece of Whatman 3 MM paper saturated with each of the following: 1. 1.5 M NaCl, 0.5 N NaOH for 10 min 2. 1.5 M NaCl, 0.5 M Tris-HCl (pH 7.5) for 5 min 3. 2X SSC for 5 min The filters were then air dried and crosslinked by UV irradiation. The filters were then subjected to digestion with Proteinase K by incubating in a solution containing 0.2% SDS, 100 mM Tris-HCl (pH 8.5), 50 mM NaCl, 10 mM EDTA (pH 8) and 50 μg/ml proteinase K at 55°C for 30 min. The filters were then transferred to a solution containing 5X SSC, 0.5% SDS and 1 mM EDTA (pH 8) and incubated at 55°C for 30 min. Prehybridization, hybridization and subsequent treatments were carried out using an ECL 3' Oligolabelling and Detection System kit (Amersham) with the following conditions: 1. prehybridization was carried out at 53°C for approximately 2 hours. 2. hybridization was carried out at 53°C in an overnight incubation using primer 501-16 (SEQ ID NO: 13) at approximately 7 ng/ml. After hybridization, the filters were washed as described in Example 7, Part D. After ECL detection, the filters were exposed to X-ray film at room temperature for 4 minutes. Among the 36,000 colonies screened, 24 individual colonies and mixtures of colonies were picked for further analysis by PCR. PCR was carried out in the same manner as described in Example 8, Part B except that a 20 μl reaction volume was used and the template was obtained by touching a pipet tip to the bacterial plate and then dipping the pipet tip in the PCR mixture. After overlayering with mineral oil. the PCR tubes were incubated in the thermal cycler at 94°C for 4 min prior to adding 0.2 μl of Taq polymerase. The following temperature regime was applied: 25 cycles 72°C 10 min 4°C soak An aliquot of the reaction mixture was separated by agarose gel electrophoresis as described in Example 7, Part C. Analysis of the ethidium bromide-stained gel revealed three positives among the 24 mixtures examined. The 3 positive mixtures were replated and probed with primer 496-2 (SEQ ID NO: 14) as described above. Prehybridization and hybridization, according to instructions in the ECL 3' Labelling and Detection System kit, were carried out at 53°C for 30 min and approximately 2 hours respectively. Washes were as described above and autoradiography was carried out for 20 min at room temperature. Analysis of the X-ray film revealed one positive among approximately 600 colonies screened. This colony was confirmed by PCR analysis with primers 501-16 (SEQ ID NO: 13) and 496-2 (SEQ ID NO: 14) as described above except the reaction volumes were 50 μl. The one positive colony mixture from above was replated at low density and probed with primer 496-2 (SEQ ID NO: 14) as described above except prehybridization and hybridization were carried out at 55°C. Filters were exposed to X-ray film for 2 min revealing 7 positives among approximately 300 colonies screened. D. Sequencing Analysis of Rat 1-EJ cDNA Plasmid DNA was isolated from 4 of the final positive colonies described in Example 8, Part C. Restriction enzyme analysis revealed that the plasmids each contained an approximately 4.8 kb cDNA insert. Nucleotide sequence analysis of one of the plasmids was carried out using the procedures described in Example 7, Part F. Results are shown in SEQ ID NO:15. In Fig. 8, the initial DNA sequence designates the sense strand of approximately 300 bases in what appears to comprise the 5' untranslated region preceding the translated portion of the rat GlcNAc T-V cDNA. The sequence immediately following is seen to code for the amino acid sequence of rat GlcNAc T-V. This region spans 2220 bases and codes for 740 amino acids and a stop codon (TAG) . The subsequent sequence appears to be an untranslated 3' region of the rat GlcNAc T-V cDNA. By restriction mapping analysis of the plasmid DNA, this 3' untranslated region of the cDNA appears to be approximately 2300 bases in length. Only the first approximately 100 bases of the 3' untranslated region are presented in SEQ ID NO:15. SEQ ID NO:16 thus provides the primary structure (amino acid sequence) of rat GlcNAc T-V as including 740 specified amino acid residues (estimated M.W.= 84,561). Six sites for possible N-linked glycosylation of the mature rat GlcNAc T-V polypeptide are marked in Fig. 10 with asterisks. Example 9. Southern Hybridizations Appropriate amounts of rat mammary tumor genomic DNA and rat liver genomic DNA were digested in parallel reactions with restriction enzymes (Bglll. Ncol. and Ncol/Xhal and BamHI/Bglll) according to the instructions of the suppliers. Restriction fragments were then separated by agarose gel electrophoresis (1.0% agarose, Tris-Acetate-EDTA buffer). The gels were then stained with ethidium bromide, excess stain was removed by soaking in TAE buffer, and the gels were photographed. The DNA in the gels was then depurinated by soaking in 0.25 N HC1 for 10 min with agitation. Prior to transfer to nitrocellulose, the DNA was denatured by soaking the gels in 0.5 N NaOH, 1.5 M NaCl for 30 min. The nitrocellulose was soaked in double distilled water for 20-30 min, and then in 10 x SSC for 20-30 min. The gel was rinsed with double distilled water and the base was neutralized by soaking the gel in 0.5 M Tris-HCl (pH 7.4), 3 M NaCl for 30 min. The DNA bands in the treated gel were then blotted to the nitrocellulose by capillary transfer in 10 x SSC overnight at room temperature. The positions of the wells and the orientation of the gel were marked on the nitrocellulose with a #1 pencil. The nitrocellulose sheet was the rinsed in 4 x SSC, air dried for 30 min, and baked in a vacuum oven at 80°C for 2 hr (until thoroughly dried) . The nitrocellulose was washed with prehybridization solution for 4 hr at 42°C. Hybridization was them carried out in an overnight incubation using an approximately 200 bp amplimer probe which was random-hexamer labeled with [ α"32 P]-CTP (See Sambrook et al. (eds.) (1989) supra) . The approximately 200 bp amplimer was made in a Taq polymerase reaction with Primer 1 (SEQ ID NO:5) and AntiPrimer 2 (SEQ ID NO:8) as described herein. The nitrocellulose was then washed twice with 2 x SSC, 0.2% SDS at 50°C for 30 min each time. The hybridized nitrocellulose was then placed on X-ray film with an intensifying screen and held overnight at -80 C to expose the film. Example 10. Isolation of Partial Mouse and Human sequences for Glc NAc T-V bv PCR PCR was carried out according to standard methods to determine whether Primers 1 and 2 could amplify a specific product from two cell lines (mouse lymphoma BW5147 and rat mammary tumor Mat Cl cells) . Total RNA and poly(A)+RNA was isolated from each cell line, and used as to generate cDNA using reverse transcriptase. These cDNA preparations served as template in parallel PCR reactions as follows: 10-50 ng template cDNA 5 μl 10 x Taq buffer (Mg-free) 3 μl 25 mM MgCl 2 1 μl dNTP mix (10 mM each) 1 μl 30 μM Primer 1 1 μl 30 μM Primer 2 38 μl sterile water 0.5 μl Taq polymerase Each reaction was overlayered with oil and then placed in a thermal cycler apparatus with the following temperature regime: 5 min 94°C 1 min 94°C 1 min 55°C 35-41 cycles 2 min 72°C 10 min 72°C The reaction products were then separated by agarose gel electrophoresis (2% agarose) . Example 11. A. Transient Expression of Rat GlcNAc T-V in COS-7 Cells The entire approximately 4.8 kb cDNA insert from one rat GlcNAc T-V clone described in Example 8, Part D was ligated into an Sail- and Notl-digested pJT-2 plasmid expression vector (Wen et al. (1992) Cell 69:559-572). COS-7 cells (CRL 1651, American Type Culture Collection, Rockville, MD) were transfected with the pJT-2 plasmid alone or with pJT-2 plasmid containing the rat GlcNAc T-V cDNA insert by electroporation as follows: 4 x 10 6 cells in 0.8 ml of DMEM (Dulbecco's Modified Minimal Medium, Gibco, Grand Island, NY) and 7.5% FBS (Fetal Bovine Serum, Bocknek, Ltd.) were transferred to a 0.4 cm cuvette and mixed with lOμg of plasmid DNA in lOμl of water. Electroporation was performed at room temperature at 1600 volts and 25 μF using a Gene Pulser apparatus (Bio-Rad Laboratories, Hercules, CA) with the pulse controller unit set at 200 ohms (Wen et al. (1988) supra) . The cells were then diluted into approximately 40 ml of DMEM, 7.5% FBS and transferred to 100 mm culture dishes. After a 17 hr incubation at 37°C, the medium was replaced and incubation continued for an additional 51 hr or 75 hr. B. Preparation of COS-7 Cells for GlcNAc T-V Activity Assay The medium from each COS-7 plasmid transfected plate was removed and the cells were rinsed with phosphate-buffered saline (PBS) . Cell scrapers were used to collect the cells, which were placed in tubes, diluted with PBS and centrifuged to pellet the cells. After the PBS had been aspirated, the cell pellet was subjected to quick freezing by immersion of the tube in liquid nitrogen. The cells were kept frozen on dry ice until resuspended in buffer for analysis by radiochemical assay and ELISA. C. Assay of GlcNAc T-V Activity Cell pellets were resuspended in 20μl MES (pH 6.0) 150 mM NaCl buffer and disrupted by sonication. The protein content of each extract was determined as described in Example 4. GlcNAc T-V activity was then determined in radiochemical and ELISA assays. The radiochemical assay uses a synthetic trisaccharide acceptor molecule (Srivastava et al. (1988) supra; Pierce et al. (1987) supra; Arango and Pierce (1988) supra; Palcic et al. (1988) Glycoconjugate J. 5.:49-63; Pierce and Arango (1986) J. Biol. Chem. 261:10772-10277; Crawely et al. (1990) Anal. Biochem. 185:112-117) . A typical assay mixture contains the following reagents dried under vacuum in a 1.5 ml centrifuge tube: 10 6 cpm of UDP-[ 3 H]-GlcNAc (25 cpm/pmol) , and 1 mM of the synthetic acceptor in a total volume of 0.01 ml. To initiate the reaction, 0.01 ml of cell extract, typically containing about 30 μg protein, in a buffer containing 50 mM MES (pH 6.0) and 1% Surfact-Amps (Triton) X-100, was added to the assay tube and incubated at 37 C several hours (e.g. , about 7 hrs) . To terminate the assay, 0.5 ml H 2 0 was added to each tube, vortexed to mix thoroughly, and then contents of the tubes were centrifuged. Radiolabeled product was separated from unincorporated substrate by virtue of its hydrophobic moiety by C-18 chromatography. Each supernatant was then loaded onto a pellicular C-18 Sep Pak column which had previously been activated with methanol and pre- equilibrated with water. The column was then washed with 200 ml H 2 0 to remove water-soluble radioactivity resulting from unreacted substrate and breakdown products. The radiolabeled product was then eluted with 100% methanol, and radioactivity was measured by liquid scintillation counting. All assays were conducted at least in duplicate for two time points and the results were averaged. The variation between the values from duplicate assays did not exceed plus or minus 5%, and typically were less than plus or minus 2% of the averaged value. The ELISA assay for GlcNAc T-V activity allows the detection of femtomole amounts of assay product, and the assay range covers a 10 6 -fold range of GlcNAc T-V activity. This assay utilizes unlabeled sugar nucleotide, the trisaccharide acceptor coupled to bovine serum albumin (BSA) , and a rabbit polyclonal antibody specific for the tetrasaccharide-BSA product of the reaction. In order to determine GlcNAc T-V activity, standard calibration curves must be generated in each assay using known amounts of GlcNAc T-V, as measured in the radiochemical assay, and then absorbance in a test sample must be correlated with a particular specific activity by comparison to the standard curve. An alternate approach to demonstrate that the full-length cDNA clone isolated does encode GlcNAc T-V, the coding sequence is fused to the N-terminal Protein A coding sequence as described in Larsen et al. (1989) Proc. Natl. Acad. Sci. USA Ji6_:8227-8231. The resultant recombinant plasmid is then introduced into mammalian cells such that cells which have incorporated the cDNA sequences survive in culture. Because the fusion protein contains the N-terminal sequences of Protein A, the fusion protein is directed to the secretion pathway and released from the cells. After removal of the cells by centrifugation, the culture medium is assayed for GlcNAc T-V activity as described herein. A portion of the cell-free medium is chromatographed over an IgG column to which the N-terminal Protein A sequences bind, causing GlcNAc T-V activity to be retained on the column. A second alternative approach for confirming that the cDNA isolated does encode GlcNAc T-V is to insert the complete cDNA into a vector under the control of regulatory sequences which will allow expression in the chosen mammalian host cells. The host cell chosen is a GlcNAc T-V-deficient variant of the mouse lymphoma BW5147 cell line, which variant is PHA 2.1; this variant cell line is described in Cummings et al. (1982) J. Biol. Chem. 257:13421-13427. An alternative GlcNAc T-V-deficient cell line is the Lec4 variant of CHO cells, described by Stanley, P. (1983) Methods Enzymol. 96:157-184. Both variant cells lines were selected for growth in the presence of the cytotoxic lectin L-phyto-hemagglutinin, which binds to the galactosylated product of GlcNAc T-V. Expression of the cDNA sequences encoding the GlcNAc T-V restores GlcNAc T-V activity and lectin sensitivity to these variant cell lines. The use of any one or more of the foregoing approaches provides confirmation that GlcNAc T-V is cloned as cDNA. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Pierce, J. Michael Shoreibah, Mohamed G. Adler, Beverly S. Fregien, Nevis L. (ii) TITLE OF INVENTION: N-Acetylglucosaminyltransferase V Coding Sequences (iii) NUMBER OF SEQUENCES: 19 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Greenlee and Winner, P.C. (B) STREET: 5370 Manhattan Circle Suite 201 (C) CITY: Boulder (D) STATE: Colorado (E) COUNTRY: USA (F) ZIP: 80303 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: 29-JUNE-1993 (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/905,795 (B) FILING DATE: 29-JUN-1992 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/016,863 (B) FILING DATE: 10-FEB-1993 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Ferber, Donna M. (B) REGISTRATION NUMBER: 33,878 (C) REFERENCE/DOCKET NUMBER: 34-92B PCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (303)499-8080 (B) TELEFAX: (303)499-8089 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: Asn Thr Asp Phe Phe lie Gly Lys Pro Thr Leu Arg 1 5 10 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Ala lie Leu Asn Gin Lys lie Glu Pro Tyr Met Pro Tyr Glu Phe 1 5 10 15 Thr (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Val Leu Asp Ser Phe Gly Thr Glu Pro Glu Phe Asn 1 5 10 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (v) FRAGMENT TYPE: internal (ix) FEATURE: (A) NAME/KEY: Region (B) LOCATION: 1..10 (D) OTHER INFORMATION: /label= UNCERTAIN /note= "AMINO ACIDS AT POSITIONS 4, 7 AND 9 WERE IDENTIFIED WITH UNCERTAINTY" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Ser Asp Pro Cys Tyr Ala Asp Tyr Glu Val 1 5 10 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iii) HYPOTHETICAL: NO (ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: at positions 6 and 21 (D) OTHER INFORMATION: /standard_name= "N IS INOSINE AT POSITIONS 6 AND 21" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: AAYACNGAYT TYTTYATHGG NAARCCNAC 27 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iii) HYPOTHETICAL: NO (ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: at positions 3, 9 and 24 (D) OTHER INFORMATION: /standard_name= "N IS INOSINE AT POSITIONS 3, 9, 24 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:6: GTNGGYTTNC CDATRAARAA RTCNGTRTT 29 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iii) HYPOTHETICAL: NO (ix) FEATURES (A) NAME/KEY: misc_difference (B) LOCATION: at positions 9 and 18 (D) OTHER INFORMATION: /standard_name= "N IS INOSINE AT POSITIONS 9, 18 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:7: ATHGARCCNT AYATGCCNTA YGARTTYAC 29 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iii) HYPOTHETICAL: NO (ix) FEATURES (A) NAME/KEY: misc_difference (B) LOCATION: at positions 3 and 15 (D) OTHER INFORMATION: /standard_name= "N IS INOSINE AT POSITIONS 3, 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: TCRTANGGCA TRTANGGYTC DATYTTYTG 29 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iϋ) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: GGGCCGATGA AGACTTCTGC G 21 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iϋ) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: GGGCTACTTC CTCTCGGTTA TTGAG 25 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iϋ) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GCTCTAATAC GACTCACTAT AGG 23 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iii) HYPOTHETICAL: NO (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: GGGTACGTGT GAATGATATC CAGGTAG 27 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iii) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: CCCGTCGACG AGAGCCAAG GGAATGGTAC 30 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iii) HYPOTHETICAL: NO (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: CCCAGCAGGT ACAGAGATGTG 20 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2624 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 299..2521 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: TGACCCCGCT CCTGGCTGTG CCTGGGACCC CAGTTCCCAG GAGCACGGTT 50 GCAGGAGAGT GACCCCGACT GCTACTGATG GTGCTTCTGC TGCTCCTCTA 100 CTAGCAGGAG TGACTCCTAC CCAGAAGTGG ACTTGGAGGA GGGTCCGTTA 150 GACCATCAGA ATGGAAGCCC GACAAGCAAG TCAGCTGACT CAGGAACCAG 200 AGTGAGGGCC ACGCACTCTC CGCCCCAGCC TGCACCATGA ACTTGCCTTC 250 CCCTTCTGCT TGTTGAGAGC CAAGGGAATG GTACATTACT AGAGAGAG 298 ATG GCT TTC TTT TCT CCC TGG AAG TTG TCC TCT CAG AAG CTG 340 Met Ala Phe Phe Ser Pro Trp Lys Leu Ser Ser Gin Lys Leu 1 5 10 GGC TTT TTC TTG GTG ACT TTT GGC TTC ATA TGG GGG ATG ATG 382 Gly Phe Phe Leu Val Thr Phe Gly Phe lie Trp Gly Met Met 15 20 25 CTT CTA CAC TTC ACC ATC CAG CAG CGA ACT CAG CCT GAG AGC 424 Leu Leu His Phe Thr lie Gin Gin Arg Thr Gin Pro Glu Ser 30 35 40 AGC TCC ATG TTG CGG GAG CAA ATC CTT GAC CTC AGC AAA AGG 466 Ser Ser Met Leu Arg Glu Gin lie Leu Asp Leu Ser Lys Arg 45 50 55 TAC ATT AAG GCA CTG GCA GAA GAG AAC AGG AAC GTG GTG GAT 508 Tyr lie Lys Ala Leu Ala Glu Glu Asn Arg Asn Val Val Asp 60 65 70 GGC CCG TAT GCC GGT GTC ATG ACA GCC TAT GAT CTG AAG AAA 550 Gly Pro Tyr Ala Gly Val Met Thr Ala Tyr Asp Leu Lys Lys 75 80 ACG CTC GCC GTG CTG CTG GAT AAC ATC TTG CAG CGC ATC GGC 592 Thr Leu Ala Val Leu Leu Asp Asn lie Leu Gin Arg lie Gly 85 90 95 AAG CTG GAG TCC AAG GTG GAC AAT CTT GTC AAC GGC ACA GGA 634 Lys Leu Glu Ser Lys Val Asp Asn Leu Val Asn Gly Thr Gly 100 105 110 GCG AAT TCT ACC AAC TCC ACC ACG GCT GTC CCC AGC TTG GTG 648 Ala Asn Ser Thr Asn Ser Thr Thr Ala Val Pro Ser Leu Val 115 120 125 TCA CTG GAG AAA ATT AAT GTG GCA GAT ATC ATT AAT GGA GTT 718 Ser Leu Glu Lys lie Asn Val Ala Asp lie lie Asn Gly Val 130 135 140 CAA GAA AAA TGT GTA TTG CCT CCT ATG GAT GGC TAC CCC CAC 760 Gin Glu Lys Cys Val Leu Pro Pro Met Asp Gly Tyr Pro His 145 150 TGC GAG GGG AAA ATC AAG TGG ATG AAA GAC ATG TGG CGG TCA 802 Cys Glu Gly Lys lie Lys Trp Met Lys Asp Met Trp Arg Ser 155 160 165 GAC CCC TGC TAC GCA GAC TAT GGA GTG GAC GGG ACC TCC TGC 844 Asp Pro Cys Tyr Ala Asp Tyr Gly Val Asp Gly Thr Ser Cys 170 175 180 TCC TTT TTT ATT TAC CTC AGT GAG GTT GAA AAT TGG TGT CCT 886 Ser Phe Phe lie Tyr Leu Ser Glu Val Glu Asn Trp Cys Pro 185 190 195 CGT TTA CCT TGG AGA GCA AAA AAT CCC TAT GAA GAA GCT GAC 928 Arg Leu Pro Trp Arg Ala Lys Asn Pro Tyr Glu Glu Ala Asp 200 205 210 CAT AAC TCA TTG GCA GAA ATC CGC ACG GAT TTT AAC ATT CTC 970 His Asn Ser Leu Ala Glu lie Arg Thr Asp Phe Asn lie Leu 215 220 TAC GGC ATG ATG AAG AAG CAT GAG GAG TTC CGG TGG ATG AGA 1012 Tyr Gly Met Met Lys Lys His Glu Glu Phe Arg Trp Met Arg 225 230 235 CTT CGG ATC CGG CGA ATG GCT GAT GCA TGG ATC CAA GCA ATC 1054 Leu Arg lie Arg Arg Met Ala Asp Ala Trp lie Gin Ala lie 240 245 250 AAG TCT CTG GCA GAG AAA CAA AAC CTA GAG AAG AGG AAA CGG 1096 Lys Ser Leu Ala Glu Lys Gin Asn Leu Glu Lys Arg Lys Arg 255 260 265 AAG AAA ATC CTT GTT CAC CTG GGG CTC CTG ACC AAG GAA TCA 1138 Lys Lys lie Leu Val His Leu Gly Leu Leu Thr Lys Glu Ser 270 275 280 GGC TTC AAG ATT GCA GAG ACA GCA TTC AGC GGT GGC CCT CTC 1180 Gly Phe Lys lie Ala Glu Thr Ala Phe Ser Gly Gly Pro Leu 285 290 GGC GAG CTC GTT CAG TGG AGT GAC TTA ATC ACA TCT CTG TAC 1222 Gly Glu Leu Val Gin Trp Ser Asp Leu lie Thr Ser Leu Tyr 295 300 305 CTG CTG GGC CAT GAC ATC CGC ATC TCA GCC TCG CTG GCT GAG 1264 Leu Leu Gly His Asp lie Arg lie Ser Ala Ser Leu Ala Glu 310 315 320 CTC AAG GAG ATT ATG AAG AAG GTT GTT GGA AAC CGG TCT GGC 1306 Leu Lys Glu lie Met Lys Lys Val Val Gly Asn Arg Ser Gly 325 330 335 TGT CCA ACT GTA GGA GAC AGA ATC GTT GAG CTT ATT TAT ATC 1348 Cys Pro Thr Val Gly Asp Arg lie Val Glu Leu lie Tyr lie 340 345 350 GAT ATT GTG GGA CTT GCT CAA TTC AAG AAA ACG CTA GGA CCA 1390 Asp lie Val Gly Leu Ala Gin Phe Lys Lys Thr Leu Gly Pro 355 360 TCC TGG GTT CAT TAC CAG TGC ATG CTC CGG GTG CTG GAC TCC 1432 Ser Trp Val His Tyr Gin Cys Met Leu Arg Val Leu Asp Ser 365 370 375 TTT GGA ACA GAA CCT GAG TTC AAT CAC GCA AGT TAC GCC CAG 1474 Phe Gly Thr Glu Pro Glu Phe Asn His Ala Ser Tyr Ala Gin 380 385 390 TCG AAA GGC CAC AAG ACC CCC TGG GGA AAG TGG AAT CTG AAC 1516 Ser Lys Gly His Lys Thr Pro Trp Gly Lys Trp Asn Leu Asn 395 400 405 CCG CAA CAG TTT TAC ACC ATG TTC CCT CAT ACC CCA GAC AAC 1558 Pro Gin Gin Phe Tyr Thr Met Phe Pro His Thr Pro Asp Asn 410 415 420 AGC TTT CTG GGC TTC GTG GTC GAG CAG CAC CTG AAC TCC AGC 1600 Ser Phe Leu Gly Phe Val Val Glu Gin His Leu Asn Ser Ser 425 430 GAC ATC CAC CAC ATT AAC GAG ATC AAA AGG CAG AAC CAG TCC 1642 Asp lie His His lie Asn Glu lie Lys Arg Gin Asn Gin Ser 435 440 445 CTT GTG TAT GGC AAA GTG GAT AGT TTC TGG AAG AAT AAG AAG 1684 Leu Val Tyr Gly Lys Val Asp Ser Phe Trp Lys Asn Lys Lys 450 455 460 ATC TAC TTG GAC ATC ATT CAC ACG TAC ATG GAA GTG CAC GCC 1726 lie Tyr Leu Asp lie lie His Thr Tyr Met Glu Val His Ala 465 470 475 1768 1810 1852 1894 1936 1978 2020 2062 2104 2146 2188 2230 2272 2314 CTG CTG AAG TAT AAG GTA ATC TGC CAA AGC TCA GAA CTA TAC 2356 Leu Leu Lys Tyr Lys Val He Cys Gin Ser Ser Glu Leu Tyr 675 680 685 AAG GAC ATC CTG GTG CCC TCC TTC TAC CCC AAG AGC AAG CAC 2398 Lys Asp He Leu Val Pro Ser Phe Tyr Pro Lys Ser Lys His 690 695 700 TGT GTG TTC CAA GGG GAT CTC CTG CTC TTC AGT TGT GCC GGG 2440 Cys Val Phe Gin Gly Asp Leu Leu Leu Phe Ser Cys Ala Gly 705 710 GCC CAC CCC ACA CAC CAG CGG ATC TGC CCC TGC CGG GAC TTC 2482 Ala His Pro Thr His Gin Arg He Cys Pro Cys Arg Asp Phe 715 720 725 ATC AAG GGC CAA GTG GCC CTC TGC AAA GAC TGC CTA 2518 He Lys Gly Gin Val Ala Leu Cys Lys Asp Cys Leu 730 735 740 TAGCATAGCC ACCCTGGATT CATTCAGATG GGAAAGACGT GGCTCCGCTG 2568 GGCAGGGCCG AGGGGCTGAA AGACAGTCAG GGACTCTGAC CAGAGCCTGA 2618 AATCTT 2624 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 740 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Met Ala Phe Phe Ser Pro Trp Lys Leu Ser Ser Gin Lys Leu Gly Phe 1 5 10 15 Phe Leu Val Thr Phe Gly Phe He Trp Gly Met Met Leu Leu His Phe 20 25 30 Thr He Gin Gin Arg Thr Gin Pro Glu Ser Ser Ser Met Leu Arg Glu 35 40 45 Gin He Leu Asp Leu Ser Lys Arg Tyr He Lys Ala Leu Ala Glu Glu 50 55 60 Asn Arg Asn Val Val Asp Gly Pro Tyr Ala Gly Val Met Thr Ala Tyr 65 70 75 80 Asp Leu Lys Lys Thr Leu Ala Val Leu Leu Asp Asn He Leu Gin Arg 85 90 95 He Gly Lys Leu Glu Ser Lys Val Asp Asn Leu Val Asn Gly Thr Gly 100 105 110 Ala Asn Ser Thr Asn Ser Thr Thr Ala Val Pro Ser Leu Val Ser Leu 115 120 125 Glu Lys He Asn Val Ala Asp He He Asn Gly Val Gin Glu Lys Cys 130 135 140 Val Leu Pro Pro Met Asp Gly Tyr Pro His Cys Glu Gly Lys He Lys 145 150 155 160 Trp Met Lys Asp Met Trp Arg Ser Asp Pro Cys Tyr Ala Asp Tyr Gly 165 170 175 Val Asp Gly Thr Ser Cys Ser Phe Phe He Tyr Leu Ser Glu Val Glu 180 185 190 Asn Trp Cys Pro Arg Leu Pro Trp Arg Ala Lys Asn Pro Tyr Glu Glu 195 200 205 Ala Asp His Asn Ser Leu Ala Glu He Arg Thr Asp Phe Asn He Leu 210 215 220 Tyr Gly Met Met Lys Lys His Glu Glu Phe Arg Trp Met Arg Leu Arg 225 230 235 240 He Arg Arg Met Ala Asp Ala Trp He Gin Ala He Lys Ser Leu Ala 245 250 255 Glu Lys Gin Asn Leu Glu Lys Arg Lys Arg Lys Lys He Leu Val His 260 265 270 Leu Gly Leu Leu Thr Lys Glu Ser Gly Phe Lys He Ala Glu Thr Ala 275 280 285 Phe Ser Gly Gly Pro Leu Gly Glu Leu Val Gin Trp Ser Asp Leu He 290 295 300 Thr Ser Leu Tyr Leu Leu Gly His Asp He Arg He Ser Ala Ser Leu 305 310 315 320 Ala Glu Leu Lys Glu He Met Lys Lys Val Val Gly Asn Arg Ser Gly 325 330 335 Cys Pro Thr Val Gly Asp Arg He Val Glu Leu He Tyr He Asp He 340 345 350 Val Gly Leu Ala Gin Phe Lys.Lys Thr Leu Gly Pro Ser Trp Val His .355 360 365 Tyr Gin Cys Met Leu Arg Val Leu Asp Ser Phe Gly Thr Glu Pro Glu 370 375 380 Phe Asn His Ala Ser Tyr Ala Gin Ser Lys Gly His Lys Thr Pro Trp 385 390 395 400 Gly Lys Trp Asn Leu Asn Pro Gin Gin Phe Tyr Thr Met Phe Pro His 405 410 415 Thr Pro Asp Asn Ser Phe Leu Gly Phe Val Val Glu Gin His Leu Asn 420 425 430 Ser Ser Asp He His His He Asn Glu He Lys Arg Gin Asn Gin Ser 435 440 445 Leu Val Tyr Gly Lys Val Asp Ser Phe Trp Lys Asn Lys Lys He Tyr 450 455 460 Leu Asp He He His Thr Tyr Met Glu Val His Ala Thr Val Tyr Gly 465 470 475 480 Ser Ser Thr Lys Asn He Pro Ser Tyr Val Lys Asn His Gly He Leu 485 490 495 Ser Gly Arg Asp Leu Gin Phe Leu Leu Arg Glu Thr Lys Leu Phe Val 500 505 510 Gly Leu Gly Phe Pro Tyr Glu Gly Pro Ala Pro Leu Glu Ala He Ala 515 520 525 Asn Gly Cys Ala Phe Leu Asn Pro Lys Phe Asn Pro Pro Lys Ser Ser 530 535 540 Lys Asn Thr Asp Phe Phe He Gly Lys Pro Thr Leu Arg Glu Leu Thr 545 550 555 560 Ser Gin His Pro Tyr Ala Glu Val Phe He Gly Arg Pro His Val Trp 565 570 575 Thr Val Asp Leu Asn Asn Arg Glu Glu Val Glu Asp Ala Val Lys Ala 580 585 590 He Leu Asn Gin Lys He Glu Pro Tyr Met Pro Tyr Glu Phe Thr Cys 595 600 605 Glu Gly Met Leu Gin Arg He Asn Ala Phe He Glu Lys Gin Asp Phe 610 615 620 Cys His Gly Gin Val Met Trp Pro Pro Leu Ser Ala Leu Gin Val Lys 625 630 635 640 Leu Ala Glu Pro Gly Gin Ser Cys Lys Gin Val Cys Gin Glu Ser Gin 645 650 655 Leu He Cys Glu Pro Ser Phe Phe Gin His Leu Asn Lys Glu Lys Asp 660 665 670 Leu Leu Lys Tyr Lys Val He Cys Gin Ser Ser Glu Leu Tyr Lys Asp 675 680 685 He Leu Val Pro Ser Phe Tyr Pro Lys Ser Lys His Cys Val Phe Gin 690 695 700 Gly Asp Leu Leu Leu Phe Ser Cys Ala Gly Ala His Pro Thr His Gin 705 710 715 720 Arg He Cys Pro Cys Arg Asp Phe He Lys Gly Gin Val Ala Leu Cys 725 730 735 Lys Asp Cys Leu 740 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 178 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (ϋi) HYPOTHETICAL: NO ( i) SEQUENCE DESCRIPTION: SEQ ID NO:17: AATACGGATT TCTTCATCGG GAAGCCTACA CTGAGAGAGC TGACATCCCA 50 GCATCCTTAC GCAGAAGTCT TCATCGGCCG GCCACACGTC TGGACTGTGG 100 ATCTCAATAA CCGAGAGGAA GTAGAAGATG CAGTAAAAGC CATCTTAAAC 150 CAGAAGATTG AGCCCTATAT GCCCTACG 178 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 179 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iii) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: AACACGGACT TTTTTATCGG GAAGCCTACA CTGAGAGAGC TCACATCCCA 50 GCACCCGTAC GCAGAAGTCT TCATCGGCCG GCCACACGTC TGGACCGTGG 100 ACCTCAATAA CCGAGAGGAA GTAGAAGACG CAGTAAAAGC CATCTTAAAC 150 CAAAAAATTG AACCCTACAT GCCCTACGA 179 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 166 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (other nucleic acid) (iii) HYPOTHETICAL: NO ( i) SEQUENCE DESCRIPTION: SEQ ID NO:19: AACACGGATT TCTTCATCGG GAAACCCACA CTGAGAGAGC TGACATCCCA 50 GCATCCTTAC GCAGAAGTCT TCATCGGCCG GCCACACGTC TGGACTGTGG 100 ATCTCAATAA CCGAGAGGAA GTAGAAGATG CAGTAAAAGC CATCTTAAAC 150 CAAAAGATTG AGCCCT 166

Claims: WE CLAIM: 1. An isolated DNA molecule comprising essentially of a nucleotide sequence encoding a polypeptide having N- acetylglucosaminyl transferase V activity, said nucleotide sequence having at least 70% homology with a nucleotide sequence as given in SEQ ID NO:15, from nucleotide 299 to nucleotide 2521. 2. The DNA molecule of claim 1 wherein said sequence encodes a mammalian GlcNAc T-V. 3. The DNA molecule of claim 2 wherein said nucleotide sequence encodes rat GlcNAc T-V. 4. The DNA molecule of claim 3 wherein said nucleotide sequence encodes a polypeptide having an amino acid sequence as given in SEQ ID NO:16. 5. The DNA molecule of claim 4 wherein said nucleotide sequence is as given in SEQ ID NO:15, from nucleotide 299 to nucleotide 2521. 6. A DNA molecule comprising the DNA sequence of claim 1 and further comprising an exogenous nucleotide sequence. 7. The DNA molecule of claim 6 wherein said exogenous nucleotide sequence is an expression vector. 8. A recombinant host cell comprising the DNA sequence of claim 1. 9. The recombinant cell of claim 8 wherein said cell is a bacterial cell. 10. The recombinant cell of claim 9 wherein said bacterial cell is Escherichia coli. 11. The recombinant cell of claim 8, wherein said cell is a mammalian cell. 12. The recombinant cell of claim 8, wherein said nucleotide sequence encodes rat GlcNAc T-V. 13. The recombinant cell of claim 12, wherein said nucleotide sequence encodes an amino acid sequence as given in SEQ ID NO:16. 14. The recombinant cell of claim 13, wherein said nucleotide sequence is as given in SEQ ID NO:15, from nucleotide 299 to nucleotide 2521. 15. The recombinant cell of claim 14 wherein said mammalian cell is derived from the COS-7 cell line. 16. A polypeptide having N-acetylglucosaminyltransferase T-V activity and characterized by being the expression product of the nucleotide sequence of claim 1. 17. The polypeptide of claim 16 wherein said polypeptide has an amino acid sequence as shown in SEQ ID NOS: 1, 2, 3 or 16. 18. The polypeptide of claim 16 wherein said polypeptide is produced by the DNA sequence of claim 12. 19. The polypeptide of claim 18 having an amino acid sequence as given in SEQ ID NO:16. 20. The DNA molecule of claim 19 wherein said amino acid is encoded by a nucleotide sequence as given in SEQ ID NO:15, from nucleotide 299 to nucleotide 2521. 21. A method of producing a polypeptide having N- Acetylglucosaminyl transferase V activity, said method comprising the steps of: (a) operably linking a nucleotide sequence encoding a polypeptide having GlcNAc T-V activity to an expression control sequence to form a GlcNAc T-V expression cassette, said nucleotide sequence having at least 70% nucleotide sequence homology with a sequence as given in SEQ ID NO:15, from nucleotide 299 to nucleotide 2521; (b) genetically engineering a cell to contain the GlcNAc T-V expression cassette of step (b) to form a GlcNAc T-V recombinant cell; (c) culturing the GlcNAc T-V recombinant cell of step (b) under conditions appropriate for expression of said GlcNAc T-V expression cassette whereby said nucleotide sequence directs the expression of a polypeptide having GlcNAc T-V activity. 22. The method of claim 21 wherein said nucleotide sequence encodes a mammalian GlcNAc T-V. 23. The method of claim 22 wherein said nucleotide sequence encodes a rat GlcNAc T-V. 24. The method of claim 23 wherein said nucleotide sequence encodes a polypeptide having GlcNAc T-V activity and having an amino acid sequence as given in SEQ ID NO:16. 25. The method of claim 24 wherein said nucleotide sequence is as given in SEQ ID NO:15, from nucleotide 299 to nucleotide 2521. 26. A DNA sequence for use in producing a polypeptide having GlcNAc T-V activity, said sequence consisting essentially of: (a) a DNA sequence encoding a polypeptide having an amino acid sequences of SEQ ID NOS: 1, 2, 3 or 16, or (b) a DNA sequence capable of hybridizing to a DNA sequence of (a) and which sequence encodes a polypeptide having GlcNAc T-V activity.

Inventors: ADLER BEVERLY S, FREGIEN NEVIS L, PIERCE J MICHAEL, SHOREIBAH MOHAMED G, ADLER, BEVERLY, S., FREGIEN, NEVIS, L., PIERCE, J., MICHAEL, SHOREIBAH, MOHAMED, G.
Applicants: ADLER BEVERLY S, AMGEN INC, FREGIEN NEVIS L, PIERCE J MICHAEL, SHOREIBAH MOHAMED G, UNIV GEORGIA, AMGEN, INC., UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Application year: 1993
Main classification: C07H21
IPC codes: A61K39, C07K7, C12N1, C12N9, C12N15, C12R1, G01N33